# EDGAR Filing Document

**Accession Number:** 0000059255
**File Stem:** 0001104659-25-107777
**Filing Date:** 2025-11
**Character Count:** 208813
**Document Hash:** 7f719553e02233eb00af9b502b3f8a43
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-25-107777.hdr.sgml**: 20251106

**ACCESSION NUMBER**: 0001104659-25-107777

**CONFORMED SUBMISSION TYPE**: 10-Q

**PUBLIC DOCUMENT COUNT**: 92

**CONFORMED PERIOD OF REPORT**: 20250930

**FILED AS OF DATE**: 20251106

**DATE AS OF CHANGE**: 20251106

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** VALHI INC /DE/
- **CENTRAL INDEX KEY:** 0000059255
- **STANDARD INDUSTRIAL CLASSIFICATION:** INDUSTRIAL INORGANIC CHEMICALS [2810]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 870110150
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 10-Q
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-05467
- **FILM NUMBER:** 251458847

**BUSINESS ADDRESS:**
- **STREET 1:** 5430 LBJ FRWY
- **STREET 2:** STE 1700
- **CITY:** DALLAS
- **STATE:** TX
- **ZIP:** 75240
- **BUSINESS PHONE:** 9722331700

**MAIL ADDRESS:**
- **STREET 1:** THREE LINCOLN CENTER
- **STREET 2:** 5430 LBJ FREEWAY SUITE 1700
- **CITY:** DALLAS
- **STATE:** TX
- **ZIP:** 75240-2620

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** LLC CORP
- **DATE OF NAME CHANGE:** 19870329

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** LIBERTY LOAN CORP
- **DATE OF NAME CHANGE:** 19800414

?xml version='1.0' encoding='ASCII'? VALHI, INC._September 30, 2025

<sup>**Table of Contents**</sup>

as

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 10-Q**

☒ **QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF**

**THE SECURITIES EXCHANGE ACT OF 1934**

**For the quarterly period ended September 30, 2025**

**OR**

☐ **TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF**

**THE SECURITIES EXCHANGE ACT OF 1934**

**For the transition period from to**

**Commission file number 1-5467**

## VALHI, INC.
**(Exact name of Registrant as specified in its charter)**

---

| | |
|:---|:---|
| **Delaware** | **87-0110150** |
| **(State or other jurisdiction of**<br>**incorporation or organization)** | **(IRS Employer**<br>**Identification No.)** |

---

**5430 LBJ Freeway, Suite 1700**

**Dallas, Texas 75240-2620**

**(Address of principal executive office)**

**Registrant's telephone number, including area code: (972) 233-1700**

**Securities registered pursuant to Section 12(b) of the Act:**

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| Common stock | VHI | NYSE |

---

**Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒&nbsp;&nbsp;&nbsp;&nbsp;No ☐**

**Whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒&nbsp;&nbsp;&nbsp;&nbsp;No ☐**

**Whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer", "accelerated filer," smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Act.**

---

| | | | |
|:---|:---|:---|:---|
| **Large accelerated filer** | **☐** | **Accelerated filer** | **☐** |
| **Non-accelerated filer**  | **☒** | **Smaller reporting company** | **☐** |
| **Emerging growth company** | **☐** |  |  |

---

**If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐**

**Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ☐ No ☒.**

**Number of shares of the registrant's common stock, $.01 par value per share, outstanding on November 3, 2025: 28,302,293**

------

<sup>**Table of Contents**</sup>

#### VALHI, INC. AND SUBSIDIARIES

#### INDEX

---

| | | | | |
|:---|:---|:---|:---|:---|
|  |  |  |  | **Page**<br>**number** |
| **Part I.** | **FINANCIAL INFORMATION** | **FINANCIAL INFORMATION** | **FINANCIAL INFORMATION** |  |
|  | Item 1. | Item 1. | Financial Statements |  |
|  |  |  | [Condensed Consolidated Balance Sheets – <br>December 31, 2024 and September 30, 2025 (unaudited)](#CONDENSEDCONSOLIDATEDBALANCESHEET) | 3 |
|  |  |  | [Condensed Consolidated Statements of Operations (unaudited) – <br>Three and nine months ended September 30, 2024 and 2025](#CONDENSEDCONSOLIDATEDSTATEMENTOPERATIONS) | 5 |
|  |  |  | [Condensed Consolidated Statements of Comprehensive Income (Loss) (unaudited) – <br>Three and nine months ended September 30, 2024 and 2025](#CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREH) | 6 |
|  |  |  | [Condensed Consolidated Statements of Stockholders' Equity (unaudited) – <br>Three and nine months ended September 30, 2024 and 2025](#CONDENSEDCONSOLIDATEDSTATEMENTOFEQUITY) | 7 |
|  |  |  | [Condensed Consolidated Statements of Cash Flows (unaudited) –<br>Nine months ended September 30, 2024 and 2025](#CONDENSEDCONSOLIDATEDCASHFLOWS) | 8 |
|  |  |  | [Notes to Condensed Consolidated Financial Statements (unaudited)](#NOTESTOCONDENSEDCONSOLIDATEDFINSTMTS) | 10 |
|  | [Item 2.](#ITEM2MGMTDISCUSSION) | [Item 2.](#ITEM2MGMTDISCUSSION) | [Management's Discussion and Analysis of Financial Condition and Results of Operations](#ITEM2MGMTDISCUSSION) | 27 |
|  | [Item 3.](#ITEM3QUANTITATIVEANDQUALITATIVEDISCLOSUR) | [Item 3.](#ITEM3QUANTITATIVEANDQUALITATIVEDISCLOSUR) | [Quantitative and Qualitative Disclosures About Market Risk](#ITEM3QUANTITATIVEANDQUALITATIVEDISCLOSUR) | 47 |
|  | [Item 4.](#ITEM4CONTROLSANDPROCEDURES) | [Item 4.](#ITEM4CONTROLSANDPROCEDURES) | [Controls and Procedures](#ITEM4CONTROLSANDPROCEDURES) | 47 |
| [**Part II.**](#PARTIIOTHERINFORMATION) | [**Part II.**](#PARTIIOTHERINFORMATION) | [**OTHER INFORMATION**](#PARTIIOTHERINFORMATION) | [**OTHER INFORMATION**](#PARTIIOTHERINFORMATION) |  |
|  |  | [Item 1.](#ITEM1LEGALPROCEEDINGS) | [Legal Proceedings](#ITEM1LEGALPROCEEDINGS) | 48 |
|  |  | [Item 1A.](#ITEM1ARISKFACTORS) | [Risk Factors](#ITEM1ARISKFACTORS) | 48 |
|  |  | [Item 6.](#ITEM6EXHIBITS) | [Exhibits](#ITEM6EXHIBITS) | 49 |

---

Items 2, 3, 4 and 5 of Part II are omitted because there is no information to report.

<sup>**Table of Contents**</sup>

#### VALHI, INC. AND SUBSIDIARIES

#### CONDENSED CONSOLIDATED BALANCE SHEETS
**(In millions)**

---

| | | |
|:---|:---|:---|
| **ASSETS** | **December 31,**  | **September 30,**  |
|  | **2024** | **2025** |
|  |  | **(unaudited)** |
| Current assets: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash and cash equivalents | $348.3 | $**183.5** |
| &nbsp;&nbsp;&nbsp;&nbsp;Restricted cash equivalents | 24.8 | **34.3** |
| &nbsp;&nbsp;&nbsp;&nbsp;Marketable securities | 1.9 | **3.1** |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts and other receivables, net | 327.8 | **366.6** |
| &nbsp;&nbsp;&nbsp;&nbsp;Inventories, net | 685.8 | **690.9** |
| &nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses and other | 65.1 | **63.0** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current assets | 1453.7 | **1341.4** |
| Other assets: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Marketable securities | 5.7 | **5.8** |
| &nbsp;&nbsp;&nbsp;&nbsp;Goodwill | 382.3 | **382.3** |
| &nbsp;&nbsp;&nbsp;&nbsp;Deferred income taxes | 53.8 | **30.6** |
| &nbsp;&nbsp;&nbsp;&nbsp;Other assets | 181.3 | **201.8** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total other assets | 623.1 | **620.5** |
| Property and equipment: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Land | 74.7 | **79.3** |
| &nbsp;&nbsp;&nbsp;&nbsp;Buildings | 282.6 | **309.8** |
| &nbsp;&nbsp;&nbsp;&nbsp;Equipment | 1312.0 | **1450.9** |
| &nbsp;&nbsp;&nbsp;&nbsp;Mining properties | 76.0 | **92.6** |
| &nbsp;&nbsp;&nbsp;&nbsp;Construction in progress | 41.7 | **45.2** |
|  | 1787.0 | **1977.8** |
| &nbsp;&nbsp;&nbsp;&nbsp;Less accumulated depreciation and amortization | 1063.6 | **1224.0** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net property and equipment | 723.4 | **753.8** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total assets | $2800.2 | $**2715.7** |

---

<sup>**Table of Contents**</sup>

#### VALHI, INC. AND SUBSIDIARIES

#### CONDENSED CONSOLIDATED BALANCE SHEETS (CONTINUED)
**(In millions)**

---

| | | |
|:---|:---|:---|
| **LIABILITIES AND STOCKHOLDERS' EQUITY** | **December 31,**  | **September 30,**  |
|  | **2024** | **2025** |
|  |  | **(unaudited)** |
| Current liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Current maturities of long-term debt | $79.0 | $**.8** |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts payable and accrued liabilities | 482.6 | **359.0** |
| &nbsp;&nbsp;&nbsp;&nbsp;Accrued environmental remediation and related costs | 59.7 | **4.0** |
| &nbsp;&nbsp;&nbsp;&nbsp;Income taxes | 22.5 | **5.2** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current liabilities | 643.8 | **369.0** |
| Noncurrent liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Long-term debt | 484.4 | **661.5** |
| &nbsp;&nbsp;&nbsp;&nbsp;Accrued pension costs | 117.6 | **125.3** |
| &nbsp;&nbsp;&nbsp;&nbsp;Accrued environmental remediation and related costs | 14.9 | **14.1** |
| &nbsp;&nbsp;&nbsp;&nbsp;Deferred income taxes | 57.7 | **50.4** |
| &nbsp;&nbsp;&nbsp;&nbsp;Other liabilities | 102.7 | **94.5** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total noncurrent liabilities | 777.3 | **945.8** |
| Equity: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Preferred stock |  | **—** |
| &nbsp;&nbsp;&nbsp;&nbsp;Common stock | .3 | **.3** |
| &nbsp;&nbsp;&nbsp;&nbsp;Additional paid-in capital | 669.9 | **670.3** |
| &nbsp;&nbsp;&nbsp;&nbsp;Retained earnings | 574.7 | **563.5** |
| &nbsp;&nbsp;&nbsp;&nbsp;Accumulated other comprehensive loss | (159.2) | **(137.0)** |
| &nbsp;&nbsp;&nbsp;&nbsp;Treasury stock, at cost | (49.6) | **(49.6)** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Valhi stockholders' equity | 1036.1 | **1047.5** |
| &nbsp;&nbsp;&nbsp;&nbsp;Noncontrolling interest in subsidiaries | 343.0 | **353.4** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total equity | 1379.1 | **1400.9** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total liabilities and equity | $2800.2 | $**2715.7** |

---

Commitments and contingencies (Notes 13, 16 and 18)

See accompanying Notes to Condensed Consolidated Financial Statements.

<sup>**Table of Contents**</sup>

#### VALHI, INC. AND SUBSIDIARIES

#### CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
**(In millions, except per share data)**

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three months ended**  | **Three months ended**  | **Nine months ended**  | **Nine months ended**  |
|  | **September 30,**  | **September 30,**  | **September 30,**  | **September 30,**  |
|  | **2024** | **2025** | **2024** | **2025** |
|  | **(unaudited)** | **(unaudited)** | **(unaudited)** | **(unaudited)** |
| Revenues and other income: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Net sales | $533.6 | $**503.5** | $1623.9 | $**1582.5** |
| &nbsp;&nbsp;&nbsp;&nbsp;Other income, net | 25.2 | **20.6** | 41.1 | **52.5** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total revenues and other income | 558.8 | **524.1** | 1665.0 | **1635.0** |
| Cost and other expense (income): |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Cost of sales | 417.3 | **442.9** | 1300.0 | **1321.3** |
| &nbsp;&nbsp;&nbsp;&nbsp;Selling, general and administrative | 74.2 | **77.6** | 217.7 | **235.3** |
| &nbsp;&nbsp;&nbsp;&nbsp;Gain on remeasurement of investment in TiO<sub>2</sub> manufacturing joint venture | (64.5) | **—** | (64.5) | **—** |
| &nbsp;&nbsp;&nbsp;&nbsp;Gain on remeasurement of earn-out liability |  | **(4.6)** |  | **(4.6)** |
| &nbsp;&nbsp;&nbsp;&nbsp;Other components of net periodic pension and OPEB expense | .6 | **.9** | 1.8 | **2.4** |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest | 13.4 | **14.9** | 36.6 | **41.9** |
| &nbsp;&nbsp;&nbsp;&nbsp;Other | (2.1) | **—** | (2.1) | **—** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total cost and other expense | 438.9 | **531.7** | 1489.5 | **1596.3** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Income (loss) before income taxes | 119.9 | **(7.6)** | 175.5 | **38.7** |
| Income tax expense  | 34.3 | **14.3** | 46.6 | **30.3** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net income (loss) | 85.6 | **(21.9)** | 128.9 | **8.4** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Noncontrolling interest in net income of subsidiaries | 28.1 | **.3** | 43.7 | **12.8** |
| Net income (loss) attributable to Valhi stockholders | $57.5 | $**(22.2)** | $85.2 | $**(4.4)** |
| Amounts attributable to Valhi stockholders: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Basic and diluted net income (loss) per share | $2.01  | $**(.78)** | $2.99  | $**(.15)** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Basic and diluted weighted average shares outstanding | 28.5 | **28.5** | 28.5 | **28.5** |

---

See accompanying Notes to Condensed Consolidated Financial Statements.

<sup>**Table of Contents**</sup>

#### VALHI, INC. AND SUBSIDIARIES

#### CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)
**(In millions)**

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three months ended**  | **Three months ended**  | **Nine months ended**  | **Nine months ended**  |
|  | **September 30,**  | **September 30,**  | **September 30,**  | **September 30,**  |
|  | **2024** | **2025** | **2024** | **2025** |
|  | **(unaudited)** | **(unaudited)** | **(unaudited)** | **(unaudited)** |
| Net income (loss) | $85.6 | $**(21.9)** | $128.9 | $**8.4** |
| Other comprehensive income (loss), net of tax: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Currency translation | 5.8 | **.2** | (10.9) | **28.4** |
| &nbsp;&nbsp;&nbsp;&nbsp;Defined benefit pension plans | .7 | **.6** | 2.1 | **1.8** |
| &nbsp;&nbsp;&nbsp;&nbsp;Other |  | **—** | (.2) | **(.1)** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total other comprehensive income (loss), net | 6.5 | **.8** | (9.0) | **30.1** |
| Comprehensive income (loss) | 92.1 | **(21.1)** | 119.9 | **38.5** |
| Comprehensive income attributable to noncontrolling interest | 29.9 | **.6** | 41.5 | **20.7** |
| Comprehensive income (loss) attributable to Valhi stockholders | $62.2 | $**(21.7)** | $78.4 | $**17.8** |

---

See accompanying Notes to Condensed Consolidated Financial Statements.

<sup>**Table of Contents**</sup>

#### VALHI, INC. AND SUBSIDIARIES

#### CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY
**(In millions)**

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Three months ended September 30, 2024 and 2025 (unaudited)** | **Three months ended September 30, 2024 and 2025 (unaudited)** | **Three months ended September 30, 2024 and 2025 (unaudited)** | **Three months ended September 30, 2024 and 2025 (unaudited)** | **Three months ended September 30, 2024 and 2025 (unaudited)** | **Three months ended September 30, 2024 and 2025 (unaudited)** | **Three months ended September 30, 2024 and 2025 (unaudited)** |
|  | <br>**Common**<br>**stock** | <br>**Additional**<br>**paid-in**<br>**capital** | <br>**Retained**<br>**earnings** | **Accumulated**<br>**other**<br>**comprehensive**<br>**loss** | <br>**Treasury**<br>**stock** | <br>**Non-**<br>**controlling**<br>**interest** | <br>**Total** |
| Balance at June 30, 2024 | $.3 | $669.9 | $499.0 | $(157.0) | $(49.6) | $324.4 | $1287.0 |
| Net income  |  |  | 57.5 |  |  | 28.1 | 85.6 |
| Other comprehensive income, net |  |  |  | 4.7 |  | 1.8 | 6.5 |
| Dividends paid to noncontrolling interest |  |  |  |  |  | (10.2) | (10.2) |
| Cash dividends - $.08 per share |  |  | (2.3) |  |  |  | (2.3) |
| Balance at September 30, 2024 | $.3 | $669.9 | $554.2 | $(152.3) | $(49.6) | $344.1 | $1366.6 |
| Balance at June 30, 2025 | $.3 | $670.3 | $588.0 | $(137.5) | $(49.6) | $358.5 | $1430.0 |
| Net income (loss) | **—** | **—** | **(22.2)** | **—** | **—** | **.3** | **(21.9)** |
| Other comprehensive income, net | **—** | **—** | **—** | **.5** | **—** | **.3** | **.8** |
| Dividends paid to noncontrolling interest | **—** | **—** | **—** | **—** | **—** | **(5.7)** | **(5.7)** |
| Cash dividends - $.08 per share | **—** | **—** | **(2.3)** | **—** | **—** | **—** | **(2.3)** |
| **Balance at September 30, 2025** | $**.3** | $**670.3** | $**563.5** | $**(137.0)** | $**(49.6)** | $**353.4** | $**1400.9** |

---

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Nine months ended September 30, 2024 and 2025 (unaudited)** | **Nine months ended September 30, 2024 and 2025 (unaudited)** | **Nine months ended September 30, 2024 and 2025 (unaudited)** | **Nine months ended September 30, 2024 and 2025 (unaudited)** | **Nine months ended September 30, 2024 and 2025 (unaudited)** | **Nine months ended September 30, 2024 and 2025 (unaudited)** | **Nine months ended September 30, 2024 and 2025 (unaudited)** |
|  | <br>**Common**<br>**stock** | <br>**Additional**<br>**paid-in**<br>**capital** | <br>**Retained**<br>**earnings** | **Accumulated**<br>**other**<br>**comprehensive**<br>**loss** | <br>**Treasury**<br>**stock** | <br>**Non-**<br>**controlling**<br>**interest** | <br>**Total** |
| Balance at December 31, 2023 | $.3 | $669.5 | $475.8 | $(145.5) | $(49.6) | $325.7 | $1276.2 |
| Net income  |  |  | 85.2 |  |  | 43.7 | 128.9 |
| Other comprehensive loss, net |  |  |  | (6.8) |  | (2.2) | (9.0) |
| Dividends paid to noncontrolling interest |  |  |  |  |  | (23.1) | (23.1) |
| Cash dividends - $.24 per share |  |  | (6.8) |  |  |  | (6.8) |
| Equity transactions with noncontrolling <br>interest, net and other |  | .4 |  |  |  |  | .4 |
| Balance at September 30, 2024 | $.3 | $669.9 | $554.2 | $(152.3) | $(49.6) | $344.1 | $1366.6 |
| Balance at December 31, 2024 | $.3 | $669.9 | $574.7 | $(159.2) | $(49.6) | $343.0 | $1379.1 |
| Net income (loss) | **—** | **—** | **(4.4)** | **—** | **—** | **12.8** | **8.4** |
| Other comprehensive income, net | **—** | **—** | **—** | **22.2** | **—** | **7.9** | **30.1** |
| Dividends paid to noncontrolling interest | **—** | **—** | **—** | **—** | **—** | **(10.3)** | **(10.3)** |
| Cash dividends - $.24 per share | **—** | **—** | **(6.8)** | **—** | **—** | **—** | **(6.8)** |
| Equity transactions with noncontrolling <br>interest, net and other | **—** | **.4** | **—** | **—** | **—** | **—** | **.4** |
| **Balance at September 30, 2025** | $**.3** | $**670.3** | $**563.5** | $**(137.0)** | $**(49.6)** | $**353.4** | $**1400.9** |

---

See accompanying Notes to Condensed Consolidated Financial Statements.

<sup>**Table of Contents**</sup>

#### VALHI, INC. AND SUBSIDIARIES

#### CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
**(In millions)**

---

| | | |
|:---|:---|:---|
|  | **Nine months ended**  | **Nine months ended**  |
|  | **September 30,**  | **September 30,**  |
|  | **2024** | **2025** |
|  | **(unaudited)** | **(unaudited)** |
| Cash flows from operating activities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Net income  | $128.9 | $**8.4** |
| &nbsp;&nbsp;&nbsp;&nbsp;Depreciation and amortization | 51.2 | **49.0** |
| &nbsp;&nbsp;&nbsp;&nbsp;Gain on remeasurement of investment in TiO<sub>2</sub> manufacturing joint venture | (64.5) | **—** |
| &nbsp;&nbsp;&nbsp;&nbsp;Gain on remeasurement of earn-out liability |  | **(4.6)** |
| &nbsp;&nbsp;&nbsp;&nbsp;Premium on issuance of senior secured notes | 6.0 | **4.4** |
| &nbsp;&nbsp;&nbsp;&nbsp;Benefit plan expense less than cash funding | (6.9) | **(5.6)** |
| &nbsp;&nbsp;&nbsp;&nbsp;Deferred income taxes | 20.0 | **17.8** |
| &nbsp;&nbsp;&nbsp;&nbsp;Contributions to TiO<sub>2</sub> manufacturing joint venture, net | (2.7) | **—** |
| &nbsp;&nbsp;&nbsp;&nbsp;Other, net | (.8) | **5.2** |
| &nbsp;&nbsp;&nbsp;&nbsp;Change in assets and liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts and other receivables, net | (67.8) | **(13.9)** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Inventories, net | 96.4 | **41.9** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Land held for development, net | 2.0 | **(4.4)** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts payable and accrued liabilities | (110.4) | **(110.6)** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accrued environmental remediation and related costs |  | **(56.5)** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Income taxes | 1.8 | **(19.8)** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts with affiliates | (20.2) | **(23.6)** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other, net | (34.8) | **(23.8)** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash used in operating activities | (1.8) | **(136.1)** |
| Cash flows from investing activities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Capital expenditures | (18.4) | **(35.8)** |
| &nbsp;&nbsp;&nbsp;&nbsp;Acquisition of remaining TiO<sub>2</sub> manufacturing joint venture interest, net of cash acquired | (156.8) | **—** |
| &nbsp;&nbsp;&nbsp;&nbsp;Purchases of marketable securities | (1.0) | **(1.9)** |
| &nbsp;&nbsp;&nbsp;&nbsp;Proceeds from disposal of marketable securities | 55.8 | **.9** |
| &nbsp;&nbsp;&nbsp;&nbsp;Other, net | 2.8 | **—** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash used in investing activities | (117.6) | **(36.8)** |
| Cash flows from financing activities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Kronos revolving credit facility: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Borrowings | 148.6 | **484.4** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Payments | (123.9) | **(425.7)** |
| &nbsp;&nbsp;&nbsp;&nbsp;Payments on long-term debt | (101.3) | **(108.0)** |
| &nbsp;&nbsp;&nbsp;&nbsp;Kronos term loan from Contran | 53.7 | **—** |
| &nbsp;&nbsp;&nbsp;&nbsp;Proceeds from issuance on senior secured notes | 80.2 | **88.0** |
| &nbsp;&nbsp;&nbsp;&nbsp;Valhi cash dividends paid | (6.8) | **(6.8)** |
| &nbsp;&nbsp;&nbsp;&nbsp;Distributions to noncontrolling interest in subsidiaries | (23.1) | **(16.3)** |
| &nbsp;&nbsp;&nbsp;&nbsp;Deferred financing fees | (9.3) | **(1.5)** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash provided by financing activities | 18.1 | **14.1** |

---

<sup>**Table of Contents**</sup>

#### VALHI, INC. AND SUBSIDIARIES

#### CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (CONTINUED)
**(In millions)**

---

| | | |
|:---|:---|:---|
|  | **Nine months ended**  | **Nine months ended**  |
|  | **September 30,**  | **September 30,**  |
|  | **2024** | **2025** |
|  | **(unaudited)** | **(unaudited)** |
| Cash, cash equivalents and restricted cash and cash equivalents - net change from: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Operating, investing and financing activities | $(101.3) | $**(158.8)** |
| &nbsp;&nbsp;&nbsp;&nbsp;Effect of exchange rates on cash | 4.4 | **4.1** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Balance at beginning of period | 462.0 | **378.6** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Balance at end of period | $365.1 | $**223.9** |
| Supplemental disclosures: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash paid for: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interest, net of amounts capitalized | $37.2 | $**47.8** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Income taxes, net | 41.1 | **48.7** |
| &nbsp;&nbsp;&nbsp;&nbsp;Noncash investing activities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Change in accruals for capital expenditures | 1.4 | **3.8** |

---

See accompanying Notes to Condensed Consolidated Financial Statements

<sup>**Table of Contents**</sup>

#### VALHI, INC. AND SUBSIDIARIES

#### NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
**September 30, 2025**

**(unaudited)**

#### Note 1 – Organization and basis of presentation:
*Organization* **–** We are majority owned by a wholly-owned subsidiary of Contran Corporation ("Contran"), which owns approximately 91% of our outstanding common stock at September 30, 2025. A majority of Contran's outstanding voting stock is held directly by Lisa K. Simmons and by family stockholders (Thomas C. Connelly (the husband of Ms. Simmons' late sister), a family-owned entity and various family trusts established for the benefit of Ms. Simmons, Mr. Connelly and their children) who are required to vote their shares of Contran voting stock in the same manner as Ms. Simmons. Such voting rights are personal to Ms. Simmons and last through April 22, 2030. The remainder of Contran's outstanding voting stock is held by another trust (the "Family Trust"), which was established for the benefit of Ms. Simmons and her late sister and their children and for which a third-party financial institution serves as trustee. Consequently, at September 30, 2025, Ms. Simmons and the Family Trust may be deemed to control Contran and us.

*Basis of Presentation –* Consolidated in this Quarterly Report are the results of our wholly-owned and majority-owned subsidiaries, including NL Industries, Inc., Kronos Worldwide, Inc., CompX International Inc., Tremont LLC, Basic Management, Inc. ("BMI") and The LandWell Company ("LandWell"). Kronos (NYSE: KRO), NL (NYSE: NL) and CompX (NYSE American: CIX) each file periodic reports with the Securities and Exchange Commission ("SEC").

The unaudited Condensed Consolidated Financial Statements contained in this Quarterly Report have been prepared on the same basis as the audited Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2024 that we filed with the SEC on March 6, 2025 (the "2024 Annual Report"). In our opinion, we have made all necessary adjustments (which include only normal recurring adjustments), in order to state fairly, in all material respects, our consolidated financial position, results of operations and cash flows as of the dates and for the periods presented. We have condensed the Consolidated Balance Sheet at December 31, 2024 contained in this Quarterly Report as compared to our audited Consolidated Financial Statements at that date, and we have omitted certain information and footnote disclosures (including those related to the Consolidated Balance Sheet at December 31, 2024) normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP"). Our results of operations for the interim periods ended September 30, 2025 may not be indicative of our operating results for the full year. The Condensed Consolidated Financial Statements contained in this Quarterly Report should be read in conjunction with our 2024 Consolidated Financial Statements contained in our 2024 Annual Report.

Effective July 16, 2024 ("Acquisition Date"), Kronos acquired the 50% joint venture interest in Louisiana Pigment Company, L.P. ("LPC") previously held by Venator Investments, Ltd. ("Venator"). Prior to the acquisition, Kronos held a 50% joint venture interest in LPC and LPC was operated as a manufacturing joint venture between Kronos and Venator. Following the acquisition, LPC became a wholly-owned subsidiary of Kronos. For financial reporting purposes, the assets acquired and liabilities assumed of LPC have been included in our Condensed Consolidated Balance Sheets as of December 31, 2024 and September 30, 2025, and the results of operations and cash flows of LPC have been included in our Condensed Consolidated Statements of Operations and Cash Flows beginning as of the Acquisition Date. See Note 18 to our Condensed Consolidated Financial Statements.

Unless otherwise indicated, references in this report to "we," "us" or "our" refer to Valhi, Inc. and its subsidiaries (NYSE: VHI), taken as a whole.

#### Note 2 – Business segment information:

---

| | | |
|:---|:---|:---|
| <br>**Business segment** | <br>**Entity** | **% controlled at**<br>**September 30, 2025** |
| Chemicals | Kronos | 81% |
| Component products | CompX | 87% |
| Real estate management and development | BMI and LandWell | 63% - 77% |

---

Our control of Kronos includes approximately 50% we hold directly and approximately 31% held directly by NL. We own approximately 83% of NL. Our control of CompX is through NL. We own approximately 63% of BMI. Our control of LandWell includes the approximately 27% we hold directly and 50% held by BMI.

<sup>**Table of Contents**</sup>

Our chief operating decision maker ("CODM") evaluates segment performance based on each segment's operating income (loss), which is defined as income (loss) before income taxes and interest expense, exclusive of certain non-recurring items (such as gains or losses on disposition of business units and other long-lived assets outside the ordinary course of business and certain legal settlements) and certain general corporate income and expense items (including securities transactions gains and losses and interest and dividend income), which are not attributable to the operations of the reportable operating segments. Interest income included in the calculation of segment operating income (loss) is not significant for the three and nine months ended September 30, 2024 and 2025.

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three months ended**  | **Three months ended**  | **Nine months ended**  | **Nine months ended**  |
|  | **September 30,**  | **September 30,**  | **September 30,**  | **September 30,**  |
|  | **2024** | **2025** | **2024** | **2025** |
|  | **(In millions)** | **(In millions)** | **(In millions)** | **(In millions)** |
| Net sales: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Chemicals | $484.7 | $**456.9** | $1464.0 | $**1441.1** |
| &nbsp;&nbsp;&nbsp;&nbsp;Component products | 33.6 | **40.0** | 107.5 | **120.6** |
| &nbsp;&nbsp;&nbsp;&nbsp;Real estate management and development | 15.3 | **6.6** | 52.4 | **20.8** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total net sales | $533.6 | $**503.5** | $1623.9 | $**1582.5** |
| Cost of sales: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Chemicals | $384.4 | $**410.4** | $1193.0 | $**1225.9** |
| &nbsp;&nbsp;&nbsp;&nbsp;Component products | 24.1 | **29.0** | 77.2 | **84.5** |
| &nbsp;&nbsp;&nbsp;&nbsp;Real estate management and development | 8.8 | **3.5** | 29.8 | **10.9** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total cost of sales | $417.3 | $**442.9** | $1300.0 | $**1321.3** |
| Gross margin: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Chemicals | $100.3 | $**46.5** | $271.0 | $**215.2** |
| &nbsp;&nbsp;&nbsp;&nbsp;Component products | 9.5 | **11.0** | 30.3 | **36.1** |
| &nbsp;&nbsp;&nbsp;&nbsp;Real estate management and development | 6.5 | **3.1** | 22.6 | **9.9** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total gross margin | $116.3 | $**60.6** | $323.9 | $**261.2** |
| Operating income (loss): |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Chemicals | $42.6 | $**(15.9)** | $105.9 | $**35.6** |
| &nbsp;&nbsp;&nbsp;&nbsp;Component products | 3.3 | **4.8** | 12.1 | **17.0** |
| &nbsp;&nbsp;&nbsp;&nbsp;Real estate management and development | 21.8 | **19.7** | 36.0 | **41.6** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total operating income  | 67.7 | **8.6** | 154.0 | **94.2** |
| General corporate items: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest income and other | 5.4 | **4.6** | 16.6 | **12.6** |
| &nbsp;&nbsp;&nbsp;&nbsp;Gain on remeasurement of investment in TiO<sub>2</sub> manufacturing joint venture | 64.5 | **—** | 64.5 | **—** |
| &nbsp;&nbsp;&nbsp;&nbsp;Gain on remeasurement of earn-out liability |  | **4.6** |  | **4.6** |
| &nbsp;&nbsp;&nbsp;&nbsp;Insurance recoveries  | 1.1 | **—** | 1.3 | **—** |
| &nbsp;&nbsp;&nbsp;&nbsp;Other components of net periodic pension and OPEB expense | (.6) | **(.9)** | (1.8) | **(2.4)** |
| &nbsp;&nbsp;&nbsp;&nbsp;Changes in market value of Valhi common stock held by subsidiaries | 3.7 | **(.1)** | 4.3 | **(1.8)** |
| &nbsp;&nbsp;&nbsp;&nbsp;General expenses, net | (8.5) | **(9.5)** | (26.8) | **(26.6)** |
| Interest expense | (13.4) | **(14.9)** | (36.6) | **(41.9)** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Income (loss) before income taxes | $119.9 | $**(7.6)** | $175.5 | $**38.7** |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three months ended** | **Three months ended** | **Nine months ended** | **Nine months ended** |
|  | **September 30,** | **September 30,** | **September 30,** | **September 30,** |
|  | **2024** | **2025** | **2024** | **2025** |
|  | **(In millions)** | **(In millions)** | **(In millions)** | **(In millions)** |
| Depreciation and amortization: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Chemicals | $17.8 | $**16.2** | $48.3 | $**46.2** |
| &nbsp;&nbsp;&nbsp;&nbsp;Component products | 1.0 | **.9** | 2.8 | **2.8** |
| &nbsp;&nbsp;&nbsp;&nbsp;Real estate management and development |  | **—** | .1 | **—** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total | $18.8 | $**17.1** | $51.2 | $**49.0** |

---

Included in the Chemicals Segment's operating income for the three and nine month periods ended September 30, 2024 is approximately $4 million and $14 million, respectively, in non-cash charges primarily related to accelerated depreciation in connection with the closure of its sulfate process line in Canada. The Chemicals Segment's operating income for the nine months ended September 30, 2024 includes $2.2 million of transaction costs incurred in connection with the LPC acquisition and an approximate $2 million charge related to workforce reductions. Infrastructure reimbursements and land related income is included in the determination of Real

<sup>**Table of Contents**</sup>

Estate Management and Development operating income. See Note 12. Segment results we report may differ from amounts separately reported by our various subsidiaries due to purchase accounting adjustments and related amortization or differences in the way we define operating income. Intersegment sales are not material. Our CODM is not regularly provided financial information related to the assets of the reportable segments, including capital expenditures, and he does not evaluate the reportable segments' performance or allocate resources to them based on assets. Therefore, total assets by reportable segment are not included in our segment disclosures.

#### Note 3 – Accounts and other receivables, net:

---

| | | |
|:---|:---|:---|
|  | **December 31,** <br>**2024** | **September 30,** <br>**2025** |
|  | **(In millions)** | **(In millions)** |
| Trade accounts receivable: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Kronos | $269.2 | $**319.4** |
| &nbsp;&nbsp;&nbsp;&nbsp;CompX | 14.2 | **18.2** |
| &nbsp;&nbsp;&nbsp;&nbsp;BMI/LandWell | .3 | **1.2** |
| VAT and other receivables | 45.9 | **30.7** |
| Refundable income taxes | 1.3 | **1.0** |
| Receivables from affiliates: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Contran - trade items | .2 | **.1** |
| &nbsp;&nbsp;&nbsp;&nbsp;Other  | .6 | **.6** |
| Allowance for doubtful accounts | (3.9) | **(4.6)** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total | $327.8 | $**366.6** |

---

#### Note 4 – Inventories, net:

---

| | | |
|:---|:---|:---|
|  | **December 31,** <br>**2024** | **September 30,** <br>**2025** |
|  | **(In millions)** | **(In millions)** |
| Raw materials: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Chemicals | $176.9 | $**114.0** |
| &nbsp;&nbsp;&nbsp;&nbsp;Component products | 5.6 | **5.8** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total raw materials | 182.5 | **119.8** |
| Work in process: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Chemicals | 52.5 | **50.6** |
| &nbsp;&nbsp;&nbsp;&nbsp;Component products | 17.6 | **20.7** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total in-process products | 70.1 | **71.3** |
| Finished products: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Chemicals | 308.3 | **360.2** |
| &nbsp;&nbsp;&nbsp;&nbsp;Component products | 5.1 | **4.5** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total finished products | 313.4 | **364.7** |
| Supplies (chemicals) | 119.8 | **135.1** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total | $685.8 | $**690.9** |

---

<sup>**Table of Contents**</sup>

#### Note 5 – Marketable securities:

---

| | | | |
|:---|:---|:---|:---|
|  | <br>**Market value** | **Cost or**<br>**amortized**<br>**cost** | <br>**Unrealized**<br>**gain, net** |
|  | **(In millions)** | **(In millions)** | **(In millions)** |
| **December 31, 2024:** |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Current assets | $1.9 | $1.9 | $— |
| &nbsp;&nbsp;&nbsp;&nbsp;Noncurrent assets | $5.7 | $5.7 | $— |
| **September 30, 2025:** |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Current assets | $**3.1** | $**3.1** | $**—** |
| &nbsp;&nbsp;&nbsp;&nbsp;Noncurrent assets | $**5.8** | $**5.5** | $**.3** |

---

Our marketable securities consist of investments in marketable equity and debt securities. We classify all of our marketable securities as available-for-sale. Our marketable equity securities are carried at fair value using quoted market prices, primarily Level 1 inputs as defined by ASC Topic 820, *Fair Value Measurements and Disclosures*, with any unrealized gains or losses on the securities recognized in other income, net on our Condensed Consolidated Statements of Operations. The fair value of our marketable debt securities is generally determined using Level 2 inputs because although these securities are traded in many cases, the market is not active and the quarter-end valuation is generally based on the last trade of the quarter, which may be several days prior to quarter end. We accumulate unrealized gains and losses on marketable debt securities as part of accumulated other comprehensive income (loss), net of related deferred income taxes. See Note 17.

#### Note 6 – Other noncurrent assets:

---

| | | |
|:---|:---|:---|
|  | **December 31,** <br>**2024** | **September 30,** <br>**2025** |
|  | **(In millions)** | **(In millions)** |
| Note receivables - OPA | $91.6 | $**114.2** |
| Pension asset | 19.8 | **22.0** |
| Operating lease right-of-use assets | 20.6 | **21.0** |
| IBNR receivables | 15.0 | **15.1** |
| Land held for development | 7.4 | **6.2** |
| Restricted cash and cash equivalents | 5.5 | **6.1** |
| Other | 21.4 | **17.2** |
| &nbsp;&nbsp;&nbsp;&nbsp;Total | $181.3 | $**201.8** |

---

<sup>**Table of Contents**</sup>

#### Note 7 – Long-term debt:

---

| | | |
|:---|:---|:---|
|  | **December 31,** <br>**2024** | **September 30,** <br>**2025** |
|  | **(In millions)** | **(In millions)** |
| Valhi: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Contran credit facility | $44.6 | $**25.0** |
| Subsidiary debt: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Kronos: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Kronos International, Inc. 9.50% Senior Secured Notes due 2029 | 365.4 | **502.3** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Kronos International, Inc. 3.75% Senior Secured Notes due 2025 | 78.3 | **—** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subordinated, Unsecured Term Loan from Contran | 53.7 | **53.7** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Revolving credit facility | 10.0 | **70.2** |
| &nbsp;&nbsp;&nbsp;&nbsp;LandWell: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Note payable to Western Alliance Business Trust | 11.4 | **11.1** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total subsidiary debt | 518.8 | **637.3** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total debt | 563.4 | **662.3** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Less current maturities | 79.0 | **.8** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total long-term debt | $484.4 | $**661.5** |

---

***Valhi*** – *Contran credit facility* – During the first nine months of 2025, we had no borrowings and repaid $19.6 million under this facility. The average interest rate on the credit facility for the nine months ended September 30, 2025 was 8.5%. At September 30, 2025, the interest rate was 8.3%, and $125.0 million was available for borrowing under this facility.

***Kronos*** *– 9.50% Senior Secured Notes due 2029 –* On September 15, 2025, Kronos International, Inc. ("KII") issued an additional €75 million principal amount of 9.50% Senior Secured Notes due 2029 (the "Additional Notes"), the proceeds of which were used to refinance the 3.75% Senior Secured Notes (€75 million aggregate principal amount) that matured in September 2025. The Additional Notes were issued as additional notes to the existing €351.174 million aggregate principal amount of 9.50% Senior Secured Notes due 2029 issued on February 12, 2024 and July 30, 2024 (the "Existing Notes"). The Additional Notes were issued at a premium of 105.0% of their principal amount, resulting in net proceeds of approximately $90 million after fees and estimated expenses. In connection with the Additional Notes offering, Kronos incurred approximately $1.7 million of debt issuance costs. The Additional Notes are fungible with the Existing Notes, are treated as a single series and have the same terms as the Existing Notes, other than their date of issuance and issue price.

At September 30, 2025, the carrying value of the 9.50% Senior Secured Notes due 2029 (€426.174 million aggregate principal amount outstanding) is $502.3 million and is stated net of $9.3 million of unamortized premium and $7.4 million of unamortized debt issuance costs. In the first quarter of 2024 Kronos recognized a non-cash pre-tax interest charge of $1.5 million included in interest expense related to the write-off of deferred financing costs.

*3.75% Senior Secured Notes due 2025 –* The 3.75% Senior Secured Notes due 2025 (€75 million aggregate principal amount) were repaid in September 2025 with proceeds from the Additional Notes offering, as described above.

*Revolving credit facility (the "Global Revolver") –* Effective July 17, 2025, Kronos completed an amendment to its Global Revolver (the "Fourth Amendment"). Among other things, the Fourth Amendment increased the maximum borrowing amount from $300 million to $350 million and increased the Belgian and German sub-limits from €30 million and €60 million to €55 million and €85 million, respectively, allowing greater access to Euro denominated borrowings. The maturity date of the Global Revolver remains July 2029. During the first nine months of 2025, Kronos borrowed $492.8 million and repaid $432.6 million under this facility. The average interest rate on outstanding borrowings under this facility for the nine months ended September 30, 2025 was 6.4%. At September 30, 2025, $70.2 million was outstanding under the Global Revolver and the average interest rate was 5.7%. At September 30, 2025, Kronos had total availability for borrowing of approximately $342 million less any amounts outstanding under this facility.

***Other*** *–* We are in compliance with all of our debt covenants at September 30, 2025.

<sup>**Table of Contents**</sup>

**Note 8 – Accounts payable and accrued liabilities:**

---

| | | |
|:---|:---|:---|
|  | **December 31,** <br>**2024** | **September 30,** <br>**2025** |
|  | **(In millions)** | **(In millions)** |
| Accounts payable: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Kronos | $232.4 | $**161.0** |
| &nbsp;&nbsp;&nbsp;&nbsp;CompX | 3.7 | **3.2** |
| &nbsp;&nbsp;&nbsp;&nbsp;BMI/LandWell | 8.0 | **2.7** |
| &nbsp;&nbsp;&nbsp;&nbsp;Distributions payable to noncontrolling interest | 5.9 | **—** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total | 250.0 | **166.9** |
| Payables to affiliates: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Contran - income taxes | 16.9 | **.5** |
| &nbsp;&nbsp;&nbsp;&nbsp;Contran - other | .2 | **2.5** |
| Employee benefits | 38.7 | **42.0** |
| Deferred income | 28.2 | **25.9** |
| Accrued sales discounts and rebates | 27.6 | **20.7** |
| Accrued development costs | 30.0 | **20.1** |
| Accrued litigation settlement | 16.4 | **16.7** |
| Operating lease liabilities | 3.5 | **4.4** |
| Interest | 11.4 | **2.5** |
| Other | 59.7 | **56.8** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total | $482.6 | $**359.0** |

---

The accrued litigation settlement is discussed in Note 16.

#### Note 9 – Other noncurrent liabilities:

---

| | | |
|:---|:---|:---|
|  | **December 31,** <br>**2024** | **September 30,** <br>**2025** |
|  | **(In millions)** | **(In millions)** |
| Accrued development costs | $26.8 | $**24.3** |
| Asset retirement obligations | 14.3 | **16.7** |
| Insurance claims and expenses | 16.6 | **16.6** |
| Operating lease liabilities | 17.1 | **16.5** |
| Deferred income | 11.8 | **8.2** |
| Other postretirement benefits | 6.7 | **6.8** |
| Employee benefits | 4.5 | **4.8** |
| Earn-out liability | 4.3 | **—** |
| Other | .6 | **.6** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total | $102.7 | $**94.5** |

---

See Notes 17 and 18 for additional details related to the acquisition earn-out liability.

<sup>**Table of Contents**</sup>

#### Note 10 – Revenue – disaggregation of sales:
The following table disaggregates the net sales of our Chemicals Segment by place of manufacture (point of origin) and to the location of the customer (point of destination), which are the categories that depict how the nature, amount, timing and uncertainty of revenue and cash flows are affected by economic factors.

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three months ended**  | **Three months ended**  | **Nine months ended**  | **Nine months ended**  |
|  | **September 30,**  | **September 30,**  | **September 30,**  | **September 30,**  |
|  | **2024** | **2025** | **2024** | **2025** |
|  | **(In millions)** | **(In millions)** | **(In millions)** | **(In millions)** |
| Net sales - point of origin: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;United States | $290.0 | $**288.7** | $810.6 | $**886.8** |
| &nbsp;&nbsp;&nbsp;&nbsp;Germany | 217.4 | **208.5** | 645.8 | **639.8** |
| &nbsp;&nbsp;&nbsp;&nbsp;Canada | 90.9 | **64.3** | 277.8 | **230.8** |
| &nbsp;&nbsp;&nbsp;&nbsp;Norway | 66.3 | **54.2** | 215.0 | **197.5** |
| &nbsp;&nbsp;&nbsp;&nbsp;Belgium | 64.6 | **54.6** | 195.2 | **185.9** |
| &nbsp;&nbsp;&nbsp;&nbsp;Eliminations | (244.5) | **(213.4)** | (680.4) | **(699.7)** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total | $484.7 | $**456.9** | $1464.0 | $**1441.1** |
| Net sales - point of destination: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Europe | $228.1 | $**204.7** | $665.6 | $**660.0** |
| &nbsp;&nbsp;&nbsp;&nbsp;North America | 179.8 | **179.9** | 528.3 | **558.3** |
| &nbsp;&nbsp;&nbsp;&nbsp;Other | 76.8 | **72.3** | 270.1 | **222.8** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total | $484.7 | $**456.9** | $1464.0 | $**1441.1** |

---

The following table disaggregates the net sales of our Component Products Segment by major product line.

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three months ended**  | **Three months ended**  | **Nine months ended**  | **Nine months ended**  |
|  | **September 30,**  | **September 30,**  | **September 30,**  | **September 30,**  |
|  | **2024** | **2025** | **2024** | **2025** |
|  | **(In millions)** | **(In millions)** | **(In millions)** | **(In millions)** |
| &nbsp;&nbsp;&nbsp;&nbsp;Net sales: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Security products | $26.6 | $**30.3** | $84.7 | $**91.2** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Marine components | 7.0 | **9.7** | 22.8 | **29.4** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total | $33.6 | $**40.0** | $107.5 | $**120.6** |

---

Substantially all of the Real Estate Management and Development Segment's sales are related to land sales.

#### Note 11 – Defined benefit pension plans:
NL administers a U.S. pension plan which has been closed to new participants since 1996. In accordance with applicable U.S. pension regulations, effective June 30, 2025 NL began the process of terminating the pension plan, which includes the purchase of annuity contracts from a third-party insurance company for the purpose of distributing benefits to plan participants. The termination process involves several steps and is expected to take between six and twelve months to complete. Following the purchase of the annuity contracts for plan participants, we will remove pension plan assets and liabilities from our Condensed Consolidated Financial Statements and a plan settlement gain or loss (which we are currently unable to estimate) will be included in our net periodic pension cost. The plan termination is expected to be completed with existing plan funds. At December 31, 2024 the U.S. pension plan had a benefit obligation of $65.2 million, plan assets of $75.7 million and a pension plan asset of $10.7 million.

<sup>**Table of Contents**</sup>

The components of our net periodic defined benefit pension cost are presented in the table below.

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three months ended**  | **Three months ended**  | **Nine months ended**  | **Nine months ended**  |
|  | **September 30,**  | **September 30,**  | **September 30,**  | **September 30,**  |
|  | **2024** | **2025** | **2024** | **2025** |
|  | **(In millions)** | **(In millions)** | **(In millions)** | **(In millions)** |
| Service cost | $1.6 | $**1.5** | $4.9 | $**4.4** |
| Interest cost  | 5.3 | **6.0** | 15.9 | **17.3** |
| Expected return on plan assets | (5.5) | **(6.1)** | (16.7) | **(17.5)** |
| Recognized net actuarial losses | 1.0 | **.8** | 2.9 | **2.4** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total | $2.4 | $**2.2** | $7.0 | $**6.6** |

---

We expect to contribute the equivalent of approximately $16 million to all of our defined benefit pension plans during 2025.

#### Note 12 – Other income, net:

---

| | | |
|:---|:---|:---|
|  | **Nine months ended**  | **Nine months ended**  |
|  | **September 30,**  | **September 30,**  |
|  | **2024** | **2025** |
|  | **(In millions)** | **(In millions)** |
| Interest income and other: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest and dividends | $16.3 | $**12.3** |
| &nbsp;&nbsp;&nbsp;&nbsp;Securities transactions, net | .3 | **.3** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total | 16.6 | **12.6** |
| Infrastructure reimbursement | 14.6 | **34.5** |
| Currency transactions, net | 4.9 | **3.2** |
| Other, net | 5.0 | **2.2** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total | $41.1 | $**52.5** |

---

*Infrastructure reimbursement* – As disclosed in Note 7 to our 2024 Annual Report, under an Owner Participation Agreement ("OPA") entered into by LandWell with the Redevelopment Agency of the City of Henderson, Nevada, as LandWell develops certain real property for commercial and residential purposes in its master planned community in Henderson, Nevada, the cost of certain public infrastructure may be reimbursed to LandWell through tax increment. LandWell received $14.2 million (all in the third quarter) and $34.2 million ($17.2 million in the second quarter and $17.0 million in the third quarter) during the first nine months of 2024 and 2025, respectively, which was recognized as other income and is evidenced by a promissory note issued to LandWell by the City of Henderson.

LandWell has agreements with certain utility providers servicing the Cadence master planned community under which certain costs incurred for the development of power infrastructure may be reimbursed to LandWell. LandWell received $.4 million and $.3 million in reimbursement during the first nine months of 2024 and 2025, respectively, for past costs incurred.

<sup>**Table of Contents**</sup>

#### Note 13 – Income taxes:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three months ended**  | **Three months ended**  | **Nine months ended**  | **Nine months ended**  |
|  | **September 30,**  | **September 30,**  | **September 30,**  | **September 30,**  |
|  | **2024** | **2025** | **2024** | **2025** |
|  | **(In millions)** | **(In millions)** | **(In millions)** | **(In millions)** |
| Expected tax expense (benefit) at U.S. federal statutory income tax rate of 21% | $25.2 | $**(1.6)** | $36.9 | $**8.1** |
| Non-U.S. tax rates | .5 | **(.5)** | .4 | **(.3)** |
| Incremental net tax expense (benefit) on earnings and losses of U.S. and non-U.S. tax group companies and other affiliates | 4.5 | **(20.8)** | .2 | **(23.3)** |
| Global intangible low-taxed income, net | 1.5 | **(1.9)** | 2.9 | **.6** |
| Valuation allowance, net | 1.3 | **17.7** | 3.8 | **23.2** |
| Nondeductible expenses | .5 | **5.1** | 1.1 | **6.4** |
| Impact of tax rate change |  | **19.3** |  | **19.3** |
| U.S. state income tax expense (benefit), net | 1.1 | **(2.5)** | 1.4 | **(2.7)** |
| Other, net | (.3) | **(.5)** | (.1) | **(1.0)** |
| &nbsp;&nbsp;&nbsp;&nbsp;Income tax expense  | $34.3 | $**14.3** | $46.6 | $**30.3** |
| Comprehensive provision for income taxes allocable to: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Net income (loss) | $34.3 | $**14.3** | $46.6 | $**30.3** |
| &nbsp;&nbsp;&nbsp;&nbsp;Other comprehensive income (loss): |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Currency translation | .7 | **—** | (1.4) | **3.6** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pension plans | .2 | **.2** | .8 | **.6** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other | .2 | **—** |  | **—** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total | $35.4 | $**14.5** | $46.0 | $**34.5** |

---

The amount shown in the preceding table of our income tax rate reconciliation for non-U.S. tax rates represents the result determined by multiplying the pre-tax earnings or losses of each of our non-U.S. subsidiaries by the difference between the applicable statutory income tax rate for each non-U.S. jurisdiction and the U.S. federal statutory tax rate. The amount shown on such table for incremental net tax expense (benefit) on earnings and losses on non-U.S. and non-tax group companies includes, as applicable, (i) deferred income taxes (or deferred income tax benefits) associated with the current year earnings (losses) of all our Chemicals Segment's non-U.S. subsidiaries, (ii) current U.S. income taxes (or current income tax benefit) including U.S. personal holding company tax, as applicable, attributable to current-year income (losses) of one of our Chemicals Segment's non-U.S. subsidiaries, which subsidiary is treated as a dual resident for U.S. income tax purposes, to the extent the current year income (losses) of such subsidiary is subject to U.S. income tax under the U.S. dual-resident provisions of the Internal Revenue Code, (iii) deferred income taxes associated with our direct investment in Kronos and (iv) current and deferred income taxes associated with distributions and earnings from our investments in LandWell and BMI.

Tax authorities are examining certain of our U.S. and non-U.S. income tax returns and may propose tax deficiencies, including penalties and interest. We believe we have adequate accruals for additional taxes and related interest expense which could ultimately result from tax examinations. We believe the ultimate disposition of tax examinations should not have a material adverse effect on our consolidated financial position, results of operations or liquidity. Excluding any potential adjustments resulting from on-going examinations by tax authorities, we currently estimate that our unrecognized tax benefits will not change materially during the next twelve months.

On July 4, 2025, the One Big Beautiful Bill Act ("OBBBA") was signed into law in the United States. The OBBBA, among other provisions, provides for bonus depreciation of qualified property, permanently modifies the interest expense deduction to use an adjusted taxable income based on a calculation similar to EBITDA and other computational changes, and makes changes to the international tax framework. The legislation has multiple effective dates, with certain provisions effective in 2025 and others implemented through 2027. The OBBBA did not have a material impact on our 2025 consolidated financial statements, and we are in the process of evaluating the impact to future years as additional provisions take effect.

On July 18, 2025, Germany enacted legislation which includes, among other provisions, an additional depreciation allowance for certain fixed assets, improvements to the research and development tax allowance and, starting in 2028, a reduction of the 15% corporate tax rate by one percentage point in each of five years until the tax rate reaches 10% in 2032. We recorded a non-cash deferred

<sup>**Table of Contents**</sup>

income tax expense of $19.3 million in the third quarter to reduce our net German deferred tax asset as a result of the reduction of the German corporate tax rate.

**Note 14 – Noncontrolling interest in subsidiaries:**

---

| | | |
|:---|:---|:---|
|  | **December 31,** <br>**2024** | **September 30,** <br>**2025** |
|  | **(In millions)** | **(In millions)** |
| Noncontrolling interest in net assets: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Kronos Worldwide | $210.3 | $**207.9** |
| &nbsp;&nbsp;&nbsp;&nbsp;NL Industries | 81.5 | **77.9** |
| &nbsp;&nbsp;&nbsp;&nbsp;CompX International | 19.0 | **17.9** |
| &nbsp;&nbsp;&nbsp;&nbsp;BMI | 18.7 | **25.1** |
| &nbsp;&nbsp;&nbsp;&nbsp;LandWell | 13.5 | **24.6** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total | $343.0 | $**353.4** |

---

---

| | | |
|:---|:---|:---|
|  | **Nine months endedSeptember 30,** | **Nine months endedSeptember 30,** |
|  | **2024** | **2025** |
|  | **(In millions)** | **(In millions)** |
| Noncontrolling interest in net income (loss) of subsidiaries: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Kronos Worldwide | $18.7 | $**(5.5)** |
| &nbsp;&nbsp;&nbsp;&nbsp;NL Industries | 8.6 | **(1.2)** |
| &nbsp;&nbsp;&nbsp;&nbsp;CompX International | 1.4 | **1.9** |
| &nbsp;&nbsp;&nbsp;&nbsp;BMI | 5.8 | **6.4** |
| &nbsp;&nbsp;&nbsp;&nbsp;LandWell | 9.2 | **11.2** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total | $43.7 | $**12.8** |

---

<sup>**Table of Contents**</sup>

#### Note 15 – Stockholders' equity:
*Accumulated other comprehensive loss* ***–*** Changes in accumulated other comprehensive income (loss) attributable to Valhi stockholders are presented in the table below.

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three months ended**  | **Three months ended**  | **Nine months ended**  | **Nine months ended**  |
|  | **September 30,**  | **September 30,**  | **September 30,**  | **September 30,**  |
|  | **2024** | **2025** | **2024** | **2025** |
|  | **(In millions)** | **(In millions)** | **(In millions)** | **(In millions)** |
| Accumulated other comprehensive income (loss) (net of tax and <br> noncontrolling interest): |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Marketable securities: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Balance at beginning of period | $1.7 | $**1.7** | $1.7 | $**1.7** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other comprehensive income: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unrealized gain arising during the period | .1 | **—** | .1 | **—** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Balance at end of period | $1.8 | $**1.7** | $1.8 | $**1.7** |
| &nbsp;&nbsp;&nbsp;&nbsp;Currency translation: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Balance at beginning of period | $(101.2) | $**(90.8)** | $(88.8) | $**(111.7)** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other comprehensive income (loss) arising during the period | 4.1 | **.1** | (8.3) | **21.0** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Balance at end of period | $(97.1) | $**(90.7)** | $(97.1) | $**(90.7)** |
| &nbsp;&nbsp;&nbsp;&nbsp;Defined benefit pension plans: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Balance at beginning of period | $(57.8) | $**(48.5)** | $(58.8) | $**(49.4)** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other comprehensive income: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amortization of prior service cost and net losses <br>included in net periodic pension cost | .6 | **.5** | 1.6 | **1.4** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Balance at end of period | $(57.2) | $**(48.0)** | $(57.2) | $**(48.0)** |
| &nbsp;&nbsp;&nbsp;&nbsp;OPEB plans: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Balance at beginning of period | $.3 | $**.1** | $.4 | $**.2** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other comprehensive income: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amortization of prior service credit and net losses <br> included in net periodic OPEB cost | (.1) | **(.1)** | (.2) | **(.2)** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Balance at end of period | $.2 | $**—** | $.2 | $**—** |
| &nbsp;&nbsp;&nbsp;&nbsp;Total accumulated other comprehensive loss: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Balance at beginning of period | $(157.0) | $**(137.5)** | $(145.5) | $**(159.2)** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other comprehensive income (loss) | 4.7 | **.5** | (6.8) | **22.2** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Balance at end of period | $(152.3) | $**(137.0)** | $(152.3) | $**(137.0)** |

---

#### Note 16 – Commitments and contingencies:

#### Lead pigment litigation – NL
NL's former operations included the manufacture of lead pigments for use in paint and lead-based paint. NL, other former manufacturers of lead pigments for use in paint and lead-based paint (together, the "former pigment manufacturers"), and the Lead Industries Association ("LIA"), which discontinued business operations in 2002, have previously been named as defendants in various legal proceedings seeking damages for personal injury, property damage and governmental expenditures allegedly caused by the use of lead-based paints. Certain of these actions were filed by or on behalf of states, counties, cities or their public housing authorities and school districts, and certain others were asserted as class actions. NL currently has no pending lead paint class action cases or pending lead paint cases brought by housing authorities, school districts or other government entities.

Pursuant to the terms of the *County of Santa Clara v. Atlantic Richfield Company, et al.* (Superior Court of the State of California, County of Santa Clara, Case No. 1-00-CV-788657) global settlement agreement, NL paid the final installment payment of $16.7 million in October 2025. The full amount of the final payment, along with additional accrued interest of approximately $1.6

<sup>**Table of Contents**</sup>

million was reimbursed to NL in October 2025 by funds already on deposit at the court that were committed to the settlement. The funds on deposit at the court are included in current restricted cash on our Condensed Consolidated Balance Sheets. See Note 18 to our 2024 Annual Report.

New cases may continue to be filed against NL. We do not know if we will incur liability in the future in respect to any of the pending or possible litigation in view of the inherent uncertainties involved in court and jury rulings. In the future, if new information regarding such matters becomes available to us (such as a final, non-appealable adverse verdict against NL or otherwise ultimately being found liable with respect to such matters), at that time we would consider such information in evaluating any remaining cases then-pending against NL as to whether it might then have become probable we have incurred liability with respect to these matters, and whether such liability, if any, could have become reasonably estimable. The resolution of any of these cases could result in the recognition of a loss contingency accrual that could have a material adverse impact on our net income for the interim or annual period during which such liability is recognized and a material adverse impact on our consolidated financial condition and liquidity.

#### Environmental matters and litigation
Our operations are governed by various environmental laws and regulations. Certain of our businesses are and have been engaged in the handling, manufacture or use of substances or compounds that may be considered toxic or hazardous within the meaning of applicable environmental laws and regulations. As with other companies engaged in similar businesses, certain of our past and current operations and products have the potential to cause environmental or other damage. Our businesses have implemented and continue to implement various policies and programs in an effort to minimize these risks. Our policy is to maintain compliance with applicable environmental laws and regulations at all of our plants and to strive to improve environmental performance and overall sustainability. Periodically we produce our Kronos Environmental Social Governance Report, which highlights Kronos' focus on sustainability of its manufacturing operations, as well as its environmental, social and governance strategy. From time to time, our businesses may be subject to environmental regulatory enforcement under U.S. and non-U.S. statutes, the resolution of which typically involves the establishment or enhancement of compliance programs. It is possible that future developments, such as stricter requirements of environmental laws and enforcement policies, could adversely affect our production, handling, use, storage, transportation, sale or disposal of such substances. We believe all of our facilities are in substantial compliance with applicable environmental laws.

Certain properties and facilities used in our former operations (primarily NL's former operations), including divested primary and secondary lead smelters and former mining locations, are the subject of civil litigation, administrative proceedings or investigations arising under federal and state environmental laws and common law. Additionally, in connection with past operating practices, we are currently involved as a defendant, potentially responsible party ("PRP") or both, pursuant to the Comprehensive Environmental Response, Compensation and Liability Act, as amended by the Superfund Amendments and Reauthorization Act ("CERCLA"), and similar state laws in various governmental and private actions associated with waste disposal sites, mining locations, and facilities that we or our predecessors, and NL or its predecessors, our subsidiaries or their predecessors currently or previously owned, operated or used, certain of which are on the United States Environmental Protection Agency's ("EPA") Superfund National Priorities List or similar state lists. These proceedings seek cleanup costs, damages for personal injury or property damage and/or damages for injury to natural resources. Certain of these proceedings involve claims for substantial amounts. Although we may be jointly and severally liable for these costs, in most cases we are only one of a number of PRPs who may also be jointly and severally liable, and among whom costs may be shared or allocated. In addition, we are occasionally named as a party in a number of personal injury lawsuits filed in various jurisdictions alleging claims related to environmental conditions alleged to have resulted from our operations.

Obligations associated with environmental remediation and related matters are difficult to assess and estimate for numerous reasons including the:

● complexity and differing interpretations of governmental regulations,

● number of PRPs and their ability or willingness to fund such allocation of costs,

● financial capabilities of the PRPs and the allocation of costs among them,

● solvency of other PRPs,

● multiplicity of possible solutions,

● number of years of investigatory, remedial and monitoring activity required,

● uncertainty over the extent, if any, to which our former operations might have contributed to the conditions allegedly giving rise to such personal injury, property damage, natural resource and related claims, and

● number of years between former operations and notice of claims and lack of information and documents about the former operations.

<sup>**Table of Contents**</sup>

In addition, the imposition of more stringent standards or requirements under environmental laws or regulations, new developments or changes regarding site cleanup costs or the allocation of costs among PRPs, solvency of other PRPs, the results of future testing and analysis undertaken with respect to certain sites or a determination that we are potentially responsible for the release of hazardous substances at other sites, could cause our expenditures to exceed our current estimates. Actual costs could exceed accrued amounts or the upper end of the range for sites for which estimates have been made, and costs may be incurred for sites where no estimates presently can be made. Further, additional environmental and related matters may arise in the future. If we were to incur any future liability, this could have a material adverse effect on our consolidated financial statements, results of operations and liquidity.

We record liabilities related to environmental remediation and related matters (including costs associated with damages for personal injury or property damage and/or damages for injury to natural resources) when estimated future expenditures are probable and reasonably estimable. We adjust such accruals as further information becomes available to us or as circumstances change. Unless the amounts and timing of such estimated future expenditures are fixed and reasonably determinable, we generally do not discount estimated future expenditures to their present value due to the uncertainty of the timing of the payout. We recognize recoveries of costs from other parties, if any, as assets when their receipt is deemed probable.

We do not know and cannot estimate the exact time frame over which we will make payments for our accrued environmental and related costs. The timing of payments depends upon a number of factors, including but not limited to the timing of the actual remediation process; which in turn depends on factors outside of our control. At each balance sheet date, we estimate the amount of the accrued environmental and related costs which we expect to pay within the next twelve months, and we classify this estimate as a current liability. We classify the remaining accrued environmental costs as a noncurrent liability.

The table below presents a summary of the activity in our accrued environmental costs during the first nine months of 2025.

---

| | |
|:---|:---|
|  | **Amount** |
|  | **(In millions)** |
| Balance at the beginning of the period | $**74.6** |
| Additions charged to expense, net | **2.4** |
| Payments, net | **(58.9)** |
| Balance at the end of the period | $**18.1** |
| Amounts recognized in the Condensed Consolidated Balance Sheet <br>at the end of the period: |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Current liabilities | $**4.0** |
| &nbsp;&nbsp;&nbsp;&nbsp;Noncurrent liabilities | **14.1** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total | $**18.1** |

---

*NL –* On a quarterly basis, NL evaluates the potential range of its liability for environmental remediation and related costs at sites where it has been named as a PRP or defendant. At September 30, 2025, NL had accrued approximately $13 million related to approximately 29 sites associated with remediation and related matters it believes are at the present time and/or in their current phase reasonably estimable. The upper end of the range of reasonably possible costs to NL for remediation and related matters for which NL believes it is possible to estimate costs is approximately $38 million, including the amount currently accrued.

In February 2025, the United States District Court for the District of New Jersey entered an order approving a consent decree relating to the Raritan Bay Slag Superfund Site ("RBS Site") in Middlesex County, New Jersey. The consent decree required the United States Army Corps of Engineers (and other federal agencies), the State of New Jersey, the Township of Old Bridge, NL, and twenty-two other private companies to pay a total of $151.1 million, plus interest, to resolve all federal and state law claims for past and future response costs under CERCLA and the New Jersey Spill Act, including natural resource damages, contribution, and indemnification, relating to the RBS Site. The consent decree is a global settlement of all such claims relating to the RBS Site and resolves a lawsuit captioned *United States of America, et al. v. NL Industries, Inc., et al.* (United States District Court for the District of New Jersey, Civil Action No. 3:24-cv-08946) as well as all claims asserted by NL and the other settling parties in NL's previously filed contribution lawsuit, *NL Industries, Inc. v. Old Bridge Township, et al.*

Under the terms of the consent decree, in the first quarter of 2025 NL paid $56.1 million, plus $.5 million interest, toward the global settlement and received approximately $9.6 million from the other private companies participating in the settlement. We recognized aggregate income of approximately $31.4 million in the fourth quarter of 2024 related to the adjustment of NL's environmental accrual related to this matter and recorded a $9.6 million receivable for the funds which NL received in the first quarter of 2025 from the other private companies participating in the settlement.

<sup>**Table of Contents**</sup>

NL believes that it is not reasonably possible to estimate the range of costs for certain sites. At September 30, 2025, there were approximately five sites for which NL is not currently able to reasonably estimate a range of costs. For these sites, generally the investigation is in the early stages, and NL is unable to determine whether or not NL actually had any association with the site, the nature of its responsibility, if any, for the contamination at the site, if any, and the extent of contamination at and cost to remediate the site. The timing and availability of information on these sites is dependent on events outside of NL's control, such as when the party alleging liability provides information to NL. At certain of these previously inactive sites, NL has received general and special notices of liability from the EPA and/or state agencies alleging that NL, sometimes with other PRPs, is liable for past and future costs of remediating environmental contamination allegedly caused by former operations. These notifications may assert that NL, along with any other alleged PRPs, is liable for past and/or future clean-up costs. As further information becomes available to us for any of these sites which would allow us to estimate a range of costs, we would at that time adjust our accruals. Any such adjustment could result in the recognition of an accrual that would have a material effect on our consolidated financial statements, results of operations and liquidity.

*Other* **–** We have also accrued approximately $5 million at September 30, 2025 for other environmental cleanup matters which represents our best estimate of the liability.

#### Insurance coverage claims – NL
NL is involved in certain legal proceedings with a number of its former insurance carriers regarding the nature and extent of the carriers' obligations to NL under insurance policies with respect to certain lead pigment and asbestos lawsuits. The issue of whether insurance coverage for defense costs or indemnity or both will be found to exist for NL's lead pigment and asbestos litigation depends upon a variety of factors, and we cannot assure you that such insurance coverage will be available.

NL has agreements with certain of its former insurance carriers pursuant to which the carriers reimburse it for a portion of its future lead pigment litigation defense costs and one such carrier reimburses us for a portion of NL's future asbestos litigation defense costs. We are not able to determine how much NL will ultimately recover from these carriers for defense costs incurred by NL because of certain issues that arise regarding which defense costs qualify for reimbursement. While NL continues to seek additional insurance recoveries, we do not know if we will be successful in obtaining reimbursement for either defense costs or indemnity. Accordingly, we recognize insurance recoveries in income only when receipt of the recovery is probable and we are able to reasonably estimate the amount of the recovery.

For a complete discussion of certain litigation involving NL and certain of its former insurance carriers, refer to our 2024 Annual Report.

#### Other litigation
In addition to the litigation described above, we and our affiliates are involved in various other environmental, contractual, product liability, patent (or intellectual property), employment and other claims and disputes incidental to our present and former businesses. In certain cases, we have insurance coverage for these items, although we do not expect additional material insurance coverage for our environmental matters. We currently believe the disposition of all of these various other claims and disputes (including asbestos-related claims), individually or in the aggregate, should not have a material adverse effect on our consolidated financial position, results of operations or liquidity beyond the accruals already provided.

<sup>**Table of Contents**</sup>

#### Note 17 – Fair value measurements and financial instruments:
The following table summarizes the valuation of our financial instruments recorded on a fair value basis as of December 31, 2024 and September 30, 2025:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Fair Value Measurements** | **Fair Value Measurements** | **Fair Value Measurements** | **Fair Value Measurements** |
|  | <br>**Total** | **Quoted** <br>**prices in**<br>**active**<br>**markets**<br>**(Level 1)** | **Significant** <br>**other**<br>**observable**<br>**input**<br>**(Level 2)** | <br>**Significant** <br>**unobservable**<br>**inputs**<br>**(Level 3)** |
|  | **(In millions)** | **(In millions)** | **(In millions)** | **(In millions)** |
| **Asset (liability)** |  |  |  |  |
| **December 31, 2024:** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Current marketable securities | $1.9 | $**—** | $1.9 | $**—** |
| &nbsp;&nbsp;&nbsp;&nbsp;Noncurrent marketable securities  | 5.7 | 2.6 | 3.1 | **—** |
| &nbsp;&nbsp;&nbsp;&nbsp;Earn-out liability  | (4.3) | **—** | **—** | (4.3) |
| **September 30, 2025:** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Current marketable securities | $**3.1** | $**—** | $**3.1** | $**—** |
| &nbsp;&nbsp;&nbsp;&nbsp;Noncurrent marketable securities  | **5.8** | **2.9** | **2.9** | **—** |
| &nbsp;&nbsp;&nbsp;&nbsp;Earn-out liability | **—** | **—** | **—** | **—** |

---

See Note 5 for amounts related to our marketable securities. See Note 18 for additional details related to the acquisition earn-out liability.

*Currency forward contract* – In order to manage currency exchange rate risk associated with Kronos' €75 million 3.75% Senior Secured Notes that matured in September 2025, in the first quarter of 2025 Kronos entered into a euro currency forward contract to purchase €25 million at an exchange rate of €1.05 per U.S. dollar. The contract was settled in August 2025 resulting in cash proceeds of $2.8 million. We recognized a currency transaction loss of $.4 million and a currency transaction gain of $2.8 million in our Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2025, respectively, associated with this contract. At September 30, 2025, Kronos had no currency forward contracts outstanding.

The following table presents the financial instruments that are not carried at fair value but which require fair value disclosure:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **December 31, 2024** | **December 31, 2024** | **September 30, 2025** | **September 30, 2025** |
|  | **Carrying**<br>**amount** | **Fair**<br>**value** | **Carrying**<br>**amount** | **Fair**<br>**value** |
|  | **(In millions)** | **(In millions)** | **(In millions)** | **(In millions)** |
| Cash, cash equivalents and restricted cash equivalents | $378.6 | $378.6 | $**223.9** | $**223.9** |
| Long-term debt: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Kronos fixed rate 9.50% Senior Secured Notes due 2029 | 365.4 | 403.4 | **502.3** | **528.7** |
| &nbsp;&nbsp;&nbsp;&nbsp;Kronos fixed rate 3.75% Senior Secured Notes due 2025 | 78.3 | 77.9 | **—** | **—** |
| &nbsp;&nbsp;&nbsp;&nbsp;Kronos revolving credit facility | 10.0 | 10.0 | **70.2** | **70.2** |
| &nbsp;&nbsp;&nbsp;&nbsp;LandWell bank note payable | 11.4 | 11.4 | **11.1** | **11.1** |

---

At September 30, 2025, the estimated market price of Kronos' 9.50% Senior Secured Notes due 2029 was €1,057 per €1,000 principal amount. The fair value of Kronos' Senior Secured Notes due 2029 was based on quoted market prices; however, these prices represented Level 2 inputs because the market in which the notes trade was not active. Due to the variable interest rate, the carrying amount of Kronos' revolving credit facility is deemed to approximate fair value. The fair value of other fixed-rate debt, which represents Level 2 inputs, is deemed to approximate carrying value. See Note 7. Due to their near-term maturities, the carrying amounts of accounts receivable and accounts payable are considered equivalent to fair value. See Notes 3 and 8.

<sup>**Table of Contents**</sup>

**Note 18 – Acquisition of Remaining Joint Venture Interest in LPC:**

Effective July 16, 2024 ("Acquisition Date"), Kronos acquired the 50% joint venture interest in LPC previously held by Venator. Prior to the acquisition, Kronos held a 50% joint venture interest in LPC and LPC was operated as a manufacturing joint venture between Kronos and Venator. Kronos acquired the 50% joint venture interest in LPC for consideration of $185 million less a working capital adjustment and an additional earn-out payment of up to $15 million. Kronos accounted for the acquisition of the interest in LPC as a business combination and, as a result of obtaining full control, LPC became a wholly-owned subsidiary of Kronos. The acquisition was financed through a borrowing of $132.1 million under Kronos' Global Revolver and the remainder paid with cash on hand.

For financial reporting purposes, the assets acquired and liabilities assumed of LPC have been included in our Condensed Consolidated Balance Sheets as of December 31, 2024 and September 30, 2025 and the results of operations and cash flows of LPC have been included in our Condensed Consolidated Statements of Operations and Cash Flows since the Acquisition Date.

Kronos remeasured its existing ownership interest in LPC to its estimated fair value at the Acquisition Date in accordance with ASC 805-10-25, for a business combination achieved in stages (because Kronos previously had an ownership interest in LPC). As a result of such remeasurement, we recognized a pre-tax gain of approximately $64.5 million in the third quarter of 2024. See Note 3 of our Consolidated Financial Statements included in our 2024 Annual Report for additional information. The estimated fair value of the earn-out as of December 31, 2024 is included in other noncurrent liabilities on the Condensed Consolidated Balance Sheets and is the line item captioned earn-out liability in Note 9. The earn-out liability is remeasured at fair value at each reporting date. During the third quarter of 2025, management determined that it is no longer probable the thresholds required to trigger payment of the earn-out will be achieved. As a result, the fair value of the earn-out liability was reduced to zero, resulting in the recognition of a non-cash gain of $4.6 million, which is disclosed as "Gain on remeasurement of earn-out liability" in our Condensed Consolidated Statements of Operations.

The following table summarizes the aggregate fair value of the consideration transferred to gain control of LPC, the current estimate for the fair value of Kronos' existing ownership interest in LPC and the amounts assigned to the identifiable assets acquired and liabilities assumed at the Acquisition Date. The final purchase price allocation indicated below was based upon management's estimate of the fair value of the acquired assets and assumed liabilities using independent third-party appraiser valuation techniques including income, cost, and market approaches. The total consideration was allocated to the assets acquired and liabilities assumed, with the excess of the consideration over the estimated fair value of the net assets acquired recorded as goodwill. Such final purchase price allocation did not change from the previously-reported preliminary purchase price allocation.

<sup>**Table of Contents**</sup>

Based on the analysis of the transaction at Acquisition Date, we recognized the following:

---

| | |
|:---|:---|
|  | **Amount** |
|  | **(In millions)** |
| Consideration: |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash consideration | $185.0 |
| &nbsp;&nbsp;&nbsp;&nbsp;Working capital adjustment | (11.0) |
| &nbsp;&nbsp;&nbsp;&nbsp;Earn-out liability | 4.2 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total fair value of consideration | 178.2 |
| &nbsp;&nbsp;&nbsp;&nbsp;Fair value of investment in TiO<sub>2</sub> manufacturing joint venture | 178.2 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total | $356.4 |
| Allocation of purchase price to identifiable assets acquired and liabilities assumed: |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash and cash equivalents | $21.3 |
| &nbsp;&nbsp;&nbsp;&nbsp;Restricted cash | 1.3 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts and other receivables, net | .2 |
| &nbsp;&nbsp;&nbsp;&nbsp;Inventories, net | 82.0 |
| &nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses and other | .6 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other assets | 10.7 |
| &nbsp;&nbsp;&nbsp;&nbsp;Property and equipment | 268.5 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts payable and accrued liabilities | (21.7) |
| &nbsp;&nbsp;&nbsp;&nbsp;Other noncurrent liabilities | (6.4) |
| &nbsp;&nbsp;&nbsp;&nbsp;Deferred tax liability | (2.7) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total net identifiable assets acquired | 353.8 |
| &nbsp;&nbsp;&nbsp;&nbsp;Goodwill | 2.6 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total | $356.4 |

---

Property and equipment will be depreciated over useful lives of 5 years to 20 years. Goodwill is related to the benefits expected as a result of the acquisition, and of the $2.6 million recorded as goodwill, $.1 million is expected to be deductible for tax purposes.

**Note 19 – Recent accounting pronouncements:**

In December 2023, the Financial Accounting Standards Board ("FASB") issued ASU 2023-09, Income Taxes (Topic 740): *Improvements to Income Tax Disclosures*. The ASU requires additional annual disclosure and disaggregation for the rate reconciliation, income taxes paid and income tax expense by federal, state and non-U.S. tax jurisdictions. In addition, the standard increases the disclosure requirements for items included in the rate reconciliation that meet a quantitative threshold. The ASU is effective for us beginning with our 2025 Annual Report. The ASU may be applied prospectively; however, entities have the option to apply it retrospectively. We are in the process of evaluating the additional disclosure requirements.

In November 2024, the FASB issued ASU No. 2024-03, *Reporting Comprehensive Income - Expense Disaggregation Disclosures*. The ASU requires additional information about specific expense categories in the notes to financial statements for both interim and annual reporting periods. The ASU is effective for us beginning with our 2027 Annual Report, and for interim reporting, in the first quarter of 2028, with early adoption permitted. We are in the process of evaluating the additional disclosure requirements.

<sup>**Table of Contents**</sup>

---

| | |
|:---|:---|
| **ITEM 2.** | **MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS** |

---

#### RESULTS OF OPERATIONS

#### Business Overview
We are primarily a holding company. We operate through our wholly-owned and majority-owned subsidiaries, including NL Industries, Inc., Kronos Worldwide, Inc., CompX International Inc., Tremont LLC, Basic Management, Inc. ("BMI") and the LandWell Company ("LandWell"). Kronos (NYSE: KRO), NL (NYSE: NL) and CompX (NYSE American: CIX) each file periodic reports with the SEC.

We have three consolidated reportable operating segments:

● *Chemicals* – Our Chemicals Segment is operated through our majority control of Kronos. Kronos is a leading global producer and marketer of value-added titanium dioxide pigments ("TiO <sub>2</sub> "). TiO <sub>2</sub> is used to impart whiteness, brightness, opacity and durability to a wide variety of products, including paints, plastics, paper, fibers and ceramics. Additionally, TiO <sub>2 </sub> is a critical component of everyday applications, such as coatings, plastics and paper, as well as many specialty products such as inks, cosmetics and pharmaceuticals.

● *Component Products* – We operate in the component products industry through our majority control of CompX. CompX is a leading manufacturer of security products used in the postal, recreational transportation, office and institutional furniture, cabinetry, tool storage, healthcare applications and a variety of other industries. CompX is also a leading manufacturer of wake enhancement systems, stainless steel exhaust systems, gauges, throttle controls, trim tabs and related hardware and accessories for the recreational marine industry.

● *Real Estate Management and Development* – We operate in real estate management and development through our majority control of BMI and LandWell. BMI and LandWell own real property in Henderson, Nevada. LandWell is engaged in efforts to develop certain land holdings for commercial, industrial and residential purposes in Henderson, Nevada.

#### General
This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Statements in this Quarterly Report that are not historical facts are forward-looking in nature and represent management's beliefs and assumptions based on currently available information. In some cases, you can identify forward-looking statements by the use of words such as "believes," "intends," "may," "should," "could," "anticipates," "expects" or comparable terminology, or by discussions of strategies or trends. Although we believe that the expectations reflected in such forward-looking statements are reasonable, we do not know if these expectations will be correct. Such statements by their nature involve substantial risks and uncertainties that could significantly impact expected results. Actual future results could differ materially from those predicted. The factors that could cause actual future results to differ materially from those described herein are the risks and uncertainties discussed in this Quarterly Report and those described from time to time in our other filings with the SEC and include, but are not limited to, the following:

● Future supply and demand for our products;

● Our ability to realize expected cost savings from strategic and operational initiatives;

● Our ability to integrate acquisitions, including Louisiana Pigment Company, L.P. ("LPC") into Kronos' operations and realize expected synergies and innovations;

● The extent of the dependence of certain of our businesses on certain market sectors;

● The cyclicality of certain of our businesses (such as Kronos' TiO <sub>2</sub> operations);

● Customer and producer inventory levels;

● Unexpected or earlier-than-expected industry capacity expansion (such as the TiO <sub>2</sub> industry);

● Changes in raw material and other operating costs (such as ore, zinc, brass, aluminum, steel and energy costs), including as a result of additional or changed tariffs on imported raw materials;

● Changes in the availability of raw materials (such as ore);

<sup>**Table of Contents**</sup>

● General global economic and political conditions that harm the worldwide economy, disrupt our supply chain, increase material and energy costs, reduce demand or perceived demand for TiO <sub>2</sub> , <sub> </sub> component products and land held for development or impair our ability to operate our facilities (including changes in the level of gross domestic product in various regions of the world, tariffs, natural disasters, terrorist acts, global conflicts and public health crises);

● Operating interruptions (including, but not limited to, labor disputes, leaks, natural disasters, fires, explosions, unscheduled or unplanned downtime, transportation interruptions, certain regional and world events or economic conditions and public health crises);

● Technology related disruptions (including, but not limited to, cyber-attacks; software implementation, upgrades or improvements; technology processing failures; or other events) related to our technology infrastructure that could impact our ability to continue operations, or at key vendors which could impact our supply chain, or at key customers which could impact their operations and cause them to curtail or pause orders;

● Competitive products and substitute products;

● Competition from Chinese suppliers with less stringent regulatory and environmental compliance requirements;

● Customer and competitor strategies;

● Potential difficulties in upgrading or implementing accounting and manufacturing software systems;

● Potential consolidation of our competitors;

● Potential consolidation of our customers;

● The impact of pricing and production decisions;

● Competitive technology positions;

● Our ability to protect or defend intellectual property rights;

● The introduction of new, or changes in existing, tariffs, trade barriers or trade disputes (including tariffs imposed by the U.S. federal government on imports from Canada, where Kronos has a manufacturing facility);

● The ability of our subsidiaries to pay us dividends;

● Uncertainties associated with new product development and the development of new product features;

● Fluctuations in currency exchange rates (such as changes in the exchange rate between the U.S. dollar and each of the euro, the Norwegian krone and the Canadian dollar and between the euro and the Norwegian krone) or possible disruptions to our business resulting from uncertainties associated with the euro or other currencies;

● Decisions to sell operating assets other than in the ordinary course of business;

● The timing and amounts of insurance recoveries;

● Our ability to renew or refinance credit facilities or other debt instruments in the future;

● Changes in interest rates;

● Our ability to maintain sufficient liquidity;

● The ultimate outcome of income tax audits, tax settlement initiatives or other tax matters, including future tax reform;

● Our ability to utilize income tax attributes, the benefits of which may or may not have been recognized under the more-likely-than-not recognition criteria;

● Environmental matters (such as those requiring compliance with emission and discharge standards for existing and new facilities, or new developments regarding environmental remediation or decommissioning obligations at sites related to our former operations);

● Government laws and regulations and possible changes therein (such as changes in government regulations which might impose various obligations on former manufacturers of lead pigment and lead-based paint, including NL, with respect to asserted health concerns associated with the use of such products) including new environmental, sustainability, health and safety or other regulations (such as those seeking to limit or classify TiO <sub>2 </sub> or its use);

● The ultimate resolution of pending litigation (such as NL's lead pigment and environmental matters);

<sup>**Table of Contents**</sup>

● Our ability to comply with covenants contained in our revolving bank credit facilities;

● Our ability to complete and comply with the conditions of our licenses and permits;

● Changes in real estate values and construction costs in Henderson, Nevada; and

● Pending or possible future litigation (such as litigation related to CompX's use of certain permitted chemicals in its productions process) or other actions.

Should one or more of these risks materialize (or the consequences of such development worsen), or should the underlying assumptions prove incorrect, actual results could differ materially from those currently forecasted or expected. We disclaim any intention or obligation to update or revise any forward-looking statement whether as a result of changes in information, future events or otherwise.

#### Operations Overview
*Quarter Ended September 30, 2025 Compared to the Quarter Ended September 30, 2024* –

We reported a net loss attributable to Valhi stockholders of $22.2 million or $.78 per diluted share in the third quarter of 2025 compared to net income attributable to Valhi stockholders of $57.5 million or $2.01 per diluted share in the third quarter of 2024. As discussed more fully below, our net income attributable to Valhi stockholders decreased from 2024 to 2025 primarily due to the net effects of:

● a non-cash gain of $64.5 million resulting from the remeasurement of the Chemicals Segment's investment in the TiO <sub>2</sub> manufacturing joint venture in 2024;

● an operating loss from our Chemicals Segment of $15.9 million in 2025 compared to operating income of $42.6 million in 2024;

● a non-cash deferred income tax expense of $19.3 million to reduce the Chemicals Segment's net German deferred tax asset as a result of the German tax rate reduction in 2025;

● a non-cash gain of $4.6 million resulting from the remeasurement of the Chemicals Segment's earn-out liability in 2025; and

● lower operating income from our Real Estate Management and Development Segment of $19.7 million in 2025 compared to $21.8 million in 2024, including income from tax increment infrastructure reimbursement of $17.0 million in 2025 and $14.2 million in 2024.

Our diluted net loss per share in the third quarter of 2025 includes:

● a loss of $.45 per share related to the recognition of a non-cash deferred income tax expense to reduce the Chemicals Segment's net German deferred tax asset as a result of the German tax rate reduction;

● income of $.31 per share related to tax increment infrastructure reimbursement; and

● income of $.08 per share due to the recognition of a non-cash gain resulting from the remeasurement of the Chemicals Segment's earn-out liability.

Our diluted net income per share in the third quarter of 2024 includes:

● income of $1.18 per share due to the recognition of a non-cash gain resulting from the remeasurement of the Chemicals Segment's investment in the TiO <sub>2</sub> manufacturing joint venture; and

● income of $.26 per share related to tax increment infrastructure reimbursement.

*Nine Months Ended September 30, 2025 Compared to the Nine Months Ended September 30, 2024* –

We reported a net loss attributable to Valhi stockholders of $4.4 million or $.15 per diluted share in the first nine months of 2025 compared to net income attributable to Valhi stockholders of $85.2 million or $2.99 per diluted share in the first nine months of 2024. Our net income attributable to Valhi stockholders decreased from 2024 to 2025 primarily due to the net effects of:

● lower operating income from our Chemicals Segment of $35.6 million in 2025 compared to operating income of $105.9

<sup>**Table of Contents**</sup>

million in 2024;

● a non-cash gain of $64.5 million resulting from the remeasurement of the Chemicals Segment's investment in the TiO <sub>2</sub> manufacturing joint venture in 2024;

● a non-cash deferred income tax expense of $19.3 million to reduce the Chemicals Segment's net German deferred tax asset as a result of the German tax rate reduction in 2025;

● higher operating income from our Real Estate Management and Development Segment of $41.6 million in 2025 compared to $36.0 million in 2024, including income from tax increment infrastructure reimbursement of $34.2 million in 2025 and $14.2 million in 2024;

● higher operating income from our Component Products Segment of $17.0 million in 2025 compared to $12.1 million in 2024; and

● a non-cash gain of $4.6 million resulting from the remeasurement of the Chemicals Segment's earn-out liability in 2025.

Our diluted net loss per share in the first nine months of 2025 includes:

● income of $.62 per share related to tax increment infrastructure reimbursement;

● a loss of $.45 per share related to the recognition of a non-cash deferred income tax expense to reduce the Chemicals Segment's net German deferred tax asset as a result of the German tax rate reduction; and

● income of $.08 per share due to the recognition of a non-cash gain resulting from the remeasurement of the Chemicals Segment's earn-out liability.

Our diluted net income per share in the first nine months of 2024 includes:

● income of $1.18 per share due to the recognition of a non-cash gain resulting from the remeasurement of the Chemicals Segment's investment in the TiO <sub>2</sub> manufacturing joint venture; and

● income of $.26 per share related to tax increment infrastructure reimbursement.

*Current Forecast for 2025* –

We currently expect consolidated operating income for 2025 to be lower as compared to 2024 primarily due to the net effects of:

● lower operating income from our Chemicals Segment in 2025 primarily due to the impacts of decreased sales volumes and higher production costs;

● higher operating income from our Real Estate Management and Development Segment in 2025 due to higher expected infrastructure reimbursements; and

● higher operating income from our Component Products Segment in 2025 due to higher expected marine components sales in 2025.

#### Segment Operating Results – 2025 Compared to 2024 –

#### Chemicals –
We consider TiO<sub>2</sub> to be a "quality of life" product, with demand affected by gross domestic product, or GDP, and overall economic conditions in our markets located in various regions of the world. Over the long-term, we expect demand for TiO<sub>2</sub> will grow by 2% to 3% per year, consistent with our expectations for the long-term growth in GDP. However, even if our Chemicals Segment and its competitors maintain consistent shares of the worldwide market, demand for TiO<sub>2</sub> in any interim or annual period may not change in the same proportion as the change in GDP, in part due to relative changes in the TiO<sub>2</sub> inventory levels of our Chemicals Segment's customers. We believe our Chemicals Segment's customers' inventory levels are influenced in part by their expectations for future changes in TiO<sub>2</sub> selling prices as well as their expectations for future availability of product. Although certain of our Chemicals Segment's TiO<sub>2 </sub>grades are considered specialty pigments, the majority of its grades and substantially all of its production are considered commodity pigment products with price and availability being the most significant competitive factors along with product quality and customer and technical support services.

<sup>**Table of Contents**</sup>

The factors having the most impact on our Chemicals Segment's reported operating results are:

● TiO <sub>2</sub> selling prices,

● our Chemicals Segment's TiO <sub>2</sub> sales and production volumes,

● manufacturing costs, particularly raw materials such as third-party feedstock, maintenance and energy-related expenses, and

● currency exchange rates (particularly the exchange rates for the U.S. dollar relative to the euro, the Norwegian krone and the Canadian dollar and the euro relative to the Norwegian krone).

Key performance indicators are our Chemicals Segment's TiO<sub>2</sub> average selling prices, the level of TiO<sub>2</sub> sales and production volumes, and the cost of our Chemicals Segment's titanium-containing feedstock purchased from third parties. TiO<sub>2 </sub>selling prices generally follow industry trends, and selling prices will increase or decrease generally as a result of competitive market pressures.

As previously reported, effective July 16, 2024 ("Acquisition Date"), Kronos acquired the 50% joint venture interest in Louisiana Pigment Company, L.P. ("LPC") previously held by Venator Investments, Ltd. ("Venator"). Prior to the acquisition, Kronos held a 50% joint venture interest in LPC. Following the acquisition, LPC became a wholly-owned subsidiary of Kronos. Kronos accounted for the acquisition as a business combination. The results of operations of LPC have been included in our results of operations beginning as of the Acquisition Date. See Note 18 to our Condensed Consolidated Financial Statements.

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **Three months ended September 30,**  | **Three months ended September 30,**  | **Three months ended September 30,**  | **Nine months ended September 30,**  | **Nine months ended September 30,**  | **Nine months ended September 30,**  |
|  | **2024** | **2025** | **% Change** | **2024** | **2025** | **% Change** |
|  | **(Dollars in millions)** | **(Dollars in millions)** |  | **(Dollars in millions)** | **(Dollars in millions)** |  |
| Net sales | $484.7 | $**456.9** | (6)% | $1464.0 | $**1441.1** | (2)% |
| Cost of sales | 384.4 | **410.4** | 7 | 1193.0 | **1225.9** | 3 |
| Gross margin | $100.3 | $**46.5** | (54) | $271.0 | $**215.2** | (21) |
| Operating income (loss) | $42.6 | $**(15.9)** | (137) | $105.9 | $**35.6** | (66) |
| Percent of net sales: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Cost of sales | 79% | **90%**  |  | 81% | **85%**  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Gross margin | 21 | **10** |  | 19 | **15** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Operating income (loss) | 9 | **(3)** |  | 7 | **2** |  |
| TiO<sub>2</sub> operating statistics: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Sales volumes\* | 130 | **126** | (3)% | 394 | **394** | —% |
| &nbsp;&nbsp;&nbsp;&nbsp;Production volumes\* | 141 | **126** | (11) | 399 | **394** | (1) |
| Percent change in TiO<sub>2</sub> net sales: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;TiO<sub>2 </sub>sales volumes |  |  | (3)% |  |  | —% |
| &nbsp;&nbsp;&nbsp;&nbsp;TiO<sub>2 </sub>product pricing |  |  | (7) |  |  | (2) |
| &nbsp;&nbsp;&nbsp;&nbsp;TiO<sub>2</sub> product mix/other |  |  | 1 |  |  | (1) |
| &nbsp;&nbsp;&nbsp;&nbsp;Changes in currency exchange rates |  |  | 3 |  |  | 1 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total |  |  | (6)% |  |  | (2)% |

---

\*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Thousands of metric tons

*Current Industry Conditions* – The first nine months of 2025 have seen unprecedented global uncertainty related to U.S. trade policies and geopolitical tensions. Our Chemicals Segment's customers have been hesitant to build inventories, given these uncertainties, which has prolonged the market downturn and impacted our Chemicals Segment's sales volumes and pricing momentum. Our Chemicals Segment started 2025 with average TiO<sub>2</sub> selling prices 2% higher than at the beginning of 2024 but its average TiO<sub>2</sub> selling prices declined 6% during the first nine months of 2025. Our Chemicals Segment's average TiO<sub>2 </sub>selling prices in the first nine months of 2025 were 2% lower than average selling prices during the first nine months of 2024. Overall, our Chemicals Segment's sales volumes have been comparable in the first nine months of 2025 and 2024 with higher overall sales volumes in both the European and North American markets offset by lower sales volumes in our export market.

<sup>**Table of Contents**</sup>

Our Chemicals Segment operated its production facilities at 93% of practical capacity utilization in the first nine months of 2024. In the first nine months of 2025, our Chemicals Segment's practical capacity utilization was 85% as it reduced operating rates at certain of its manufacturing facilities in response to lower demand.

The following table shows our Chemicals Segment's capacity utilization rates during 2024 and 2025.

---

| | | |
|:---|:---|:---|
| 1<br>|  |  |
|  | **Production Capacity Utilization Rates** | **Production Capacity Utilization Rates** |
|  | **2024** | **2025** |
| First quarter | 87% | 93% |
| Second quarter | 99% | 81% |
| Third quarter | 92% | 80% |

---

Excluding the effect of changes in currency exchange rates and unabsorbed fixed costs, our Chemicals Segment's cost of sales per metric ton of TiO<sub>2</sub> sold in the third quarter and the first nine months of 2025 was lower as compared to the same periods in 2024 due to decreases in per metric ton production costs.

*Net Sales* – Our Chemicals Segment's net sales in the third quarter of 2025 decreased 6%, or $27.8 million, compared to the third quarter of 2024 primarily due to the net effects of a 7% decrease in average TiO<sub>2 </sub>selling prices (which decreased net sales by approximately $33 million), a 3% decrease in sales volumes (which decreased net sales by approximately $13 million) and changes in product mix (which increased net sales by approximately $4 million). In addition, our Chemicals Segment estimates that changes in currency exchange rates (primarily the euro) increased its net sales by approximately $14 million in the third quarter of 2025 as compared to the third quarter of 2024. TiO<sub>2</sub> selling prices will increase or decrease generally as a result of competitive market pressures, changes in the relative level of supply and demand as well as changes in raw material and other manufacturing costs.

Our Chemicals Segment's sales volumes decreased 3% in the third quarter of 2025 as compared to the third quarter of 2024 primarily due to lower sales volumes in its European and export markets somewhat offset by higher sales volumes in its North American market.

Our Chemicals Segment's net sales in the first nine months of 2025 decreased 2%, or $22.9 million, compared to the first nine months of 2024 primarily due to the effects of a 2% decrease in average TiO<sub>2</sub> selling prices (which decreased net sales by approximately $32 million) and changes in product mix (which decreased net sales by approximately $2 million). In addition, our Chemicals Segment estimates that changes in currency exchange rates (primarily the euro) increased its net sales by approximately $11 million in the first nine months of 2025 as compared to the first nine months of 2024.

Our Chemicals Segment's sales volumes in the first nine months of 2025 were comparable to the same period in 2024 with higher overall sales volumes in its North American and European markets offset by lower sales volumes in its export market.

*Cost of Sales and Gross Margin* – Our Chemicals Segment's cost of sales increased by $26.0 million, or 7%, in the third quarter of 2025 compared to the third quarter of 2024 due to the net effects of unfavorable fixed cost absorption due to reduced operating rates at certain of our Chemicals Segment's manufacturing facilities, higher cost inventory produced in the second quarter relative to the same quarter of 2024 and included in cost of sales in the third quarter and currency fluctuations (primarily the euro). Our Chemicals Segment's unabsorbed fixed production costs related to decreased production volumes in the third quarter of 2025 were approximately $27 million. Cost of sales in the third quarter of 2024 includes a charge of approximately $4 million in non-cash charges related to accelerated depreciation in connection with the closure of its sulfate process line in Canada.

Our Chemicals Segment's cost of sales as a percentage of net sales increased to 90% in the third quarter of 2025 compared to 79% in the same period of 2024 primarily due to the unfavorable fixed cost absorption and currency fluctuations, as discussed above.

Our Chemicals Segment's gross margin as a percentage of net sales decreased to 10% in the third quarter of 2025 compared to 21% in the third quarter of 2024. As discussed and quantified above, our Chemicals Segment's gross margin as a percentage of net sales decreased primarily due to lower average TiO<sub>2</sub> selling prices and lower production volumes resulting in unfavorable fixed cost absorption.

Our Chemicals Segment's cost of sales increased by $32.9 million, or 3%, in the first nine months of 2025 compared to the first nine months of 2024 due to the effects of approximately $45 million in additional unabsorbed fixed production costs recognized as a result of reduced operating rates at our Chemicals Segment's production facilities somewhat offset by lower production costs of approximately $11 million (primarily raw materials) and favorable currency fluctuations (primarily the euro). Cost of sales in the first

<sup>**Table of Contents**</sup>

nine months of 2024 includes a charge of approximately $2 million related to workforce reductions and approximately $14 million in non-cash charges primarily related to accelerated depreciation in connection with the closure of our Chemicals Segment's sulfate process line in Canada.

Our Chemicals Segment's cost of sales as a percentage of net sales increased to 85% in the first nine months of 2025 compared to 81% in the same period of 2024 primarily due to unfavorable fixed cost absorption somewhat offset by lower production costs and currency fluctuations noted above.

Our Chemicals Segment's gross margin as a percentage of net sales decreased to 15% in the first nine months of 2025 compared to 19% in the first nine months of 2024. As discussed and quantified above, our Chemicals Segment's gross margin as a percentage of net sales decreased primarily due to the unfavorable effects of lower fixed cost absorption and lower average selling prices.

*Operating Income (Loss)* – Our Chemicals Segment's operating income decreased by $58.5 million to an operating loss of $15.9 million in the third quarter of 2025 compared to operating income of $42.6 million in the third quarter of 2024 as a result of the factors impacting gross margin discussed above. We estimate that changes in currency exchange rates increased our Chemicals Segment's operating loss by approximately $4 million in the third quarter of 2025 as compared to the same period in 2024, as discussed in the effects of currency exchange rates section below.

Our Chemicals Segment's operating income decreased by $70.3 million to $35.6 million in the first nine months of 2025 compared to operating income of $105.9 million in the first nine months of 2024 as a result of the factors impacting gross margin discussed above. We estimate that changes in currency exchange rates increased our Chemicals Segment's operating income by approximately $5 million in the first nine months of 2025 as compared to the same period in 2024, as further discussed below.

Our Chemicals Segment's operating income (loss) is net of amortization of purchase accounting adjustments made in conjunction with our acquisitions of interests in NL and Kronos. As a result, we recognize additional depreciation expense above the amounts Kronos reports separately, substantially all of which is included within cost of sales. We recognized additional depreciation expense of $1.6 million and $2.0 million in the first nine months of 2025 and 2024, respectively, which reduced our reported Chemicals Segment's operating income as compared to amounts reported by Kronos.

*Currency Exchange Rates* – Our Chemicals Segment has substantial operations and assets located outside the United States (primarily in Germany, Belgium, Norway and Canada). The majority of our Chemicals Segment's sales from non-U.S. operations are denominated in currencies other than the U.S. dollar, principally the euro, other major European currencies and the Canadian dollar. A portion of our Chemicals Segment's sales generated from its non-U.S. operations is denominated in the U.S. dollar (and consequently our Chemicals Segment's non-U.S. operations will generally hold U.S. dollars from time to time). Certain raw materials used in all our Chemicals Segment's production facilities, primarily titanium-containing feedstocks, are purchased primarily in U.S. dollars, while labor and other production and administrative costs are incurred primarily in local currencies. Consequently, the translated U.S. dollar value of our Chemicals Segment's non-U.S. sales and operating results are subject to currency exchange rate fluctuations which may favorably or unfavorably impact reported earnings and may affect the comparability of period-to-period operating results. In addition to the impact of the translation of sales and expenses over time, our Chemicals Segment's non-U.S. operations also generate currency transaction gains and losses which primarily relate to (i) the difference between the currency exchange rates in effect when non-local currency sales or operating costs (primarily U.S. dollar denominated) are initially accrued and when such amounts are settled with the non-local currency, (ii) changes in currency exchange rates during time periods when our Chemicals Segment's non-U.S. operations are holding non-local currency (primarily U.S. dollars), and (iii) relative changes in the aggregate fair value of currency forward contracts held from time to time. We periodically use currency forward contracts to manage a portion of our currency exchange risk, and relative changes in the aggregate fair value of any currency forward contracts we hold from time to time serves in part to mitigate the currency transaction gains or losses we would recognize from the first two items described above.

Fluctuations in currency exchange rates had the following effects on our Chemicals Segment's sales and operating income (loss) for the periods indicated.

<sup>**Table of Contents**</sup>

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Impact of changes in currency exchange rates** | **Impact of changes in currency exchange rates** | **Impact of changes in currency exchange rates** | **Impact of changes in currency exchange rates** | **Impact of changes in currency exchange rates** | **Impact of changes in currency exchange rates** |
| **Three months ended September 30, 2025 vs September 30, 2024** | **Three months ended September 30, 2025 vs September 30, 2024** | **Three months ended September 30, 2025 vs September 30, 2024** | **Three months ended September 30, 2025 vs September 30, 2024** | **Three months ended September 30, 2025 vs September 30, 2024** | **Three months ended September 30, 2025 vs September 30, 2024** |
|  |  |  |  | **Translation** |  |
|  |  |  |  | **gains -** | **Total currency** |
|  | **Transaction gains (losses) recognized** | **Transaction gains (losses) recognized** | **Transaction gains (losses) recognized** | **impact of** | **impact** |
|  | **2024** | **2025** | **Change** | **rate changes** | **2025 vs 2024** |
|  | **(In millions)** | **(In millions)** | **(In millions)** | **(In millions)** | **(In millions)** |
| **Impact on:** |  |  |  |  |  |
| Net sales | $— | $— | $— | $14 | $14 |
| Operating income (loss) | 3 | (2) | (5) | 1 | (4) |

---

The $14 million increase in our Chemicals Segment's net sales (translation gains) was caused primarily by a weakening of the U.S. dollar relative to the euro, as its euro-denominated sales were translated into more U.S. dollars in 2025 as compared to 2024. The strengthening of the U.S. dollar relative to the Canadian dollar and weakening of the U.S. dollar relative to the Norwegian krone in 2025 did not have a significant effect on our Chemicals Segment's net sales, as a substantial portion of the sales generated by our Chemicals Segment's Canadian and Norwegian operations is denominated in the U.S. dollar.

The $4 million increase in our Chemicals Segment's operating loss was comprised of the following:

● Lower net currency transaction gains of approximately $5 million primarily caused by relative changes in currency exchange rates at each applicable balance sheet date between the U.S. dollar and the euro, Canadian dollar and the Norwegian krone, and between the euro and the Norwegian krone, which causes increases or decreases, as applicable, in U.S. dollar-denominated receivables and payables and U.S. dollar currency held by our Chemicals Segment's non-U.S. operations, and in Norwegian krone denominated receivables and payables held by our Chemicals Segment's non-U.S. operations. As discussed in Note 17 to our Condensed Consolidated Financial Statements, in order to manage currency exchange rate risk associated with the maturity in September 2025 of Kronos' €75 million 3.75% Senior Secured Notes due 2025, in the first quarter of 2025, our Chemicals Segment entered into a currency forward contract to purchase €25 million at an exchange rate of €1.05 per U.S. dollar. The contract was settled in August 2025, resulting in an overall transaction gain of $2.8 million. Of this amount, a $.4 million currency transaction loss was included in our Condensed Consolidated Statement of Operations for the three months ended September 30, 2025, and

● There was minimal impact from the effect of the rate changes on translation gains and losses.

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Impact of changes in currency exchange rates** | **Impact of changes in currency exchange rates** | **Impact of changes in currency exchange rates** | **Impact of changes in currency exchange rates** | **Impact of changes in currency exchange rates** | **Impact of changes in currency exchange rates** |
| **Nine months ended September 30, 2025 vs September 30, 2024** | **Nine months ended September 30, 2025 vs September 30, 2024** | **Nine months ended September 30, 2025 vs September 30, 2024** | **Nine months ended September 30, 2025 vs September 30, 2024** | **Nine months ended September 30, 2025 vs September 30, 2024** | **Nine months ended September 30, 2025 vs September 30, 2024** |
|  |  |  |  | **Translation** |  |
|  |  |  |  | **gains -** | **Total currency** |
|  | **Transaction gains recognized** | **Transaction gains recognized** | **Transaction gains recognized** | **impact of** | **impact** |
|  | **2024** | **2025** | **Change** | **rate changes** | **2025 vs 2024** |
|  | **(In millions)** | **(In millions)** | **(In millions)** | **(In millions)** | **(In millions)** |
| **Impact on:** |  |  |  |  |  |
| Net sales | $— | $— | $— | $11 | $11 |
| Operating income | 5 | 3 | (2) | 7 | 5 |

---

The $11 million increase in our Chemicals Segment's net sales (translation gains) was caused primarily by a weakening of the U.S. dollar relative to the euro, as its euro-denominated sales were translated into more U.S. dollars in 2025 as compared to 2024. The strengthening of the U.S. dollar relative to the Canadian dollar and the weakening of the U.S. dollar relative to the Norwegian krone in 2025 did not have a significant effect on the reported amount of our Chemicals Segment's net sales, as a substantial portion of the sales generated by our Chemicals Segment's Canadian and Norwegian operations is denominated in the U.S. dollar.

The $5 million increase in our Chemicals Segment's operating income was comprised of the following:

● Lower net currency transaction gains of approximately $2 million primarily caused by relative changes in currency exchange rates at each applicable balance sheet date between the U.S. dollar and the euro, Canadian dollar and the Norwegian krone, and between the euro and the Norwegian krone, which causes increases or decreases, as applicable, in U.S. dollar-denominated receivables and payables and U.S. dollar currency held by our Chemicals Segment's non-U.S. operations, and in Norwegian krone denominated receivables and payables held by our Chemicals Segment's non-U.S. operations. As discussed in Note 17 to our Condensed Consolidated Financial Statements, in order to manage currency

<sup>**Table of Contents**</sup>

exchange rate risk associated with the maturity in September 2025 of Kronos' €75 million 3.75% Senior Secured Notes due 2025, in the first quarter of 2025, our Chemicals Segment entered into a currency forward contract to purchase €25 million at an exchange rate of €1.05 per U.S. dollar. The contract was settled in August 2025, resulting in a $2.8 million currency transaction gain in our Condensed Consolidated Statement of Operations for the nine months ended September 30, 2025, and

● Approximately $7 million from net currency translation gains primarily caused by a strengthening of the U.S. dollar relative to the Canadian dollar, as local currency-denominated operating costs were translated into fewer U.S. dollars in 2025 as compared to 2024. The effect of the weakening of the U.S. dollar relative to the euro and Norwegian krone had a minimal effect in 2025 as compared to 2024.

*Outlook –* Overall, our Chemicals Segment's customer demand remained weak in the third quarter of 2025, continuing the softening trend that began earlier in the year. High interest rates and sustained economic uncertainty, driven by global tariff and trade tensions, continue to contribute to cautious customer spending. Our Chemicals Segment does not expect sales volumes to improve meaningfully in the near-term and, although it believes customer inventory levels remain low, our Chemicals Segment is taking additional actions in the fourth quarter of 2025 to reduce its inventory levels by further lowering its operating rates to better align with current demand levels. Given the current depressed demand environment and margins, our Chemicals Segment believes it is prudent to reduce its operating rates in the fourth quarter to reduce inventory and position its plants to improve operating costs at lower utilization rates. These measures are expected to improve operating cash flows as our Chemicals Segment focuses on maximizing liquidity to manage through the current challenging demand market and to be positioned to respond when market dynamics improve.

In 2025, the TiO<sub>2</sub> market has experienced significant capacity reductions, including previously announced shutdowns or curtailments by multiple producers, such as recently announced facility closures in China and certain European jurisdictions in the third quarter of 2025. Our Chemicals Segment believes it may gain market share from these developments both from current and potential customers primarily in Europe. Although Our Chemicals Segment believes customer inventories are low, its customers' near-term outlook remains uncertain. Certain customers have notified our Chemicals Segment that they intend to curtail production in the fourth quarter due to expected low downstream demand. In North America, downstream demand remains below historical norms across all end-use customers driven by low consumer confidence and lack of housing market mobility driven by high mortgage rates and home prices, which continue to delay the housing market recovery.

Given the challenging market environment discussed above, our Chemicals Segment remains committed to implementing additional cost reduction initiatives to improve its long-term cost structure, to ensure it remains competitive, and to capitalize on potential market share opportunities. Our Chemicals Segment is currently implementing targeted workforce reductions across its operating locations impacting both manufacturing and selling, general and administrative costs. These reductions include union supported employees, which take longer to negotiate, and our Chemicals Segment cannot yet quantify the impact of such initiatives. However, our Chemicals Segment expects these workforce reductions will have a more significant financial impact than its 2023 and 2024 reductions. Beyond headcount cost savings, our Chemicals Segment is reviewing costs with all its partners, suppliers and vendors which its expects to result in cost reductions that will contribute to its cost savings.

Pressure from lower demand and favorable TiO<sub>2 </sub>availability has caused our Chemicals Segment's selling prices to decrease since the beginning of 2025. Raw material, energy, and other input costs continue to trend lower, and our Chemicals Segment expects this moderation to continue through the remainder of 2025 as lower cost inventory works its way through cost of sales. However, our Chemicals Segment expects fourth quarter operating results to be lower than the third quarter and to report lower operating results for the full year of 2025 as compared to 2024 due to weaker than expected demand, continued pricing pressure, and lower fixed cost absorption as a result of reduced operating rates. The capacity reductions noted above and the implementation of anti-dumping duties in various jurisdictions, among other factors, should lead to pricing upside in 2026. Current profit margins are unsustainable, and our Chemicals Segment will need to achieve price increases, targeted market share gain opportunities, and successfully execute on its cost reduction efforts noted above to achieve reasonable profit margins.

Our Chemicals Segment acquired full control of LPC in July 2024. Our Chemicals Segment believes this acquisition adds value to its customers and enables it to better serve the North American marketplace by expanding its product offerings and increasing sales to new and existing customers while realizing significant synergies, including commercial, overhead, and supply chain optimization. Our Chemicals Segment is in the process of fully integrating the additional LPC production capacity and expects the acquisition to positively impact its earnings. However, soft demand, competitive pressures and additional debt service costs from increased borrowings will limit this impact in the near term. During our Chemicals Segment's planned fourth quarter curtailment, our Chemicals Segment is investing in technological and manufacturing improvements to the LPC facility which are expected to improve the flexibility, quality and cost effectiveness of the facility over the long term.

<sup>**Table of Contents**</sup>

In July 2025, our Chemicals Segment increased the maximum borrowings under its credit facility from $300 million to $350 million to provide additional liquidity for general corporate purposes. In September 2025, our Chemicals Segment successfully refinanced its €75 million 3.75% Senior Secured Notes due in September 2025 by issuing €75 million in additional 9.50% Senior Secured Notes due 2029 at an effective rate of 7.8%. Our Chemicals Segment expects its cash on hand to improve as it reduces inventory levels over the next several quarters. With no near-term debt maturities, significant borrowing availability under our Chemicals Segment's revolving credit facility and cash on hand, our Chemicals Segment believes it is well-positioned to finance its working capital and capital expenditure needs.

Our expectations for the TiO<sub>2</sub> industry and our Chemicals Segment's operations are based on certain factors beyond our control. Our Chemicals Segment's operations are affected by global and regional economic, political, and regulatory factors, and it has experienced global market disruptions. Future impacts on our Chemicals Segment's operations will depend on, among other things, future energy costs, the effects of newly enacted tariffs in jurisdictions where our Chemicals Segment or its customers and suppliers operate, its success in implementing mitigation strategies, and the impact of economic conditions, consumer confidence, and geopolitical events on its operations or those of its customers and suppliers, all of which remain uncertain and cannot be predicted.

#### Component Products –
Our Component Products Segment's product offerings consist of a significantly large number of products that have a wide variation in selling price and manufacturing cost, which results in certain practical limitations on its ability to quantify the impact of changes in individual product sales quantities and selling prices on the segment's net sales, cost of sales and gross margin. In addition, small variations in period-to-period net sales, cost of sales and gross margin can result from changes in the relative mix of our Component Products Segment's products sold. The key performance indicator for our Component Products Segment is operating income**.**

Our Component Products Segment's operating income in the third quarter of 2025 was $4.8 million compared to $3.3 million in the third quarter of 2024. Operating income for the first nine months of 2025 was $17.0 million compared to $12.1 million for the comparable prior year period. Our Component Products Segment's operating income increased in the third quarter and for the first nine months of 2025 due to higher sales and gross margin at each of the security products and marine components reporting units.

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **Three months ended September 30,**  | **Three months ended September 30,**  | **Three months ended September 30,**  | **Nine months ended September 30,**  | **Nine months ended September 30,**  | **Nine months ended September 30,**  |
|  | **2024** | **2025** | **% Change** | **2024** | **2025** | **% Change** |
|  | **(Dollars in millions)** | **(Dollars in millions)** |  | **(Dollars in millions)** | **(Dollars in millions)** |  |
| Net sales: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Security products | $26.6 | $**30.3** | 14% | $84.7 | $**91.2** | 8% |
| &nbsp;&nbsp;&nbsp;&nbsp;Marine components | 7.0 | **9.7** | 36 | 22.8 | **29.4** | 29 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total net sales | 33.6 | **40.0** | 19 | 107.5 | **120.6** | 12 |
| Cost of sales | 24.1 | **29.0** | 20 | 77.2 | **84.5** | 9 |
| Gross margin | $9.5 | $**11.0** | 16 | $30.3 | $**36.1** | 19 |
| Operating income | $3.3 | $**4.8** | 42 | $12.1 | $**17.0** | 40 |
| Percent of net sales: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Cost of sales | 72% | **72%** |  | 72% | **70%**  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Gross margin | 28 | **28** |  | 28 | **30** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Operating income | 10 | **12** |  | 11 | **14** |  |

---

*Net Sales* – Our Component Products Segment's net sales increased $6.4 million and $13.1 million in the third quarter and for the first nine months of 2025, respectively, compared to the same periods in 2024 due to higher security products sales to the government security market and higher marine component sales to various markets including the towboat, government and industrial markets. Relative to prior year, the increase in third quarter security products sales was primarily due to $4.0 million higher sales to the government security market and $.3 million higher sales to the gas station security market, partially offset by $.7 million lower sales to the healthcare market and $.3 million lower sales to the tool storage market. Relative to 2024, the increase in security products sales for the first nine months of 2025 was primarily due to $8.9 million higher sales to the government security market and $.5 million higher sales to the gas station security market, partially offset by lower sales to a variety of other markets including $1.3 million lower sales to the transportation market, $.9 million lower sales to the tool storage market and $.4 million lower contract plating sales. Relative to prior year, the increase in third quarter marine component sales was primarily due to $1.2 million higher sales to the industrial market, $.9 million higher sales to the towboat market and $.5 million higher sales to the government market. Relative to 2024, the increase in marine component sales for the first nine months of 2025 was primarily due to $3.2 million higher sales to the towboat market, $3.1 million higher sales to the government market and $1.0 million higher sales to the industrial market, partially offset by $.9 million lower sales to the center console market.

<sup>**Table of Contents**</sup>

*Cost of Sales and Gross Margin* – Our Component Products Segment's cost of sales as a percentage of net sales in the third quarter of 2025 is consistent with the same period in 2024. As a result, gross margin as a percentage of net sales in the third quarter of 2025 was comparable to the same period in 2024 primarily due to lower security products gross margin percentage offset by higher marine components gross margin percentage. Security products gross margin as a percentage of net sales for the third of 2025 decreased compared to the same period in 2024 primarily due to higher cost inventory produced during the second quarter of 2025 and sold in the third quarter of 2025 and higher employee-related costs including salaries, benefits and medical expense partially offset by increased coverage of fixed costs as a result of higher sales. Marine components gross margin as a percentage of net sales increased in the third quarter of 2025 compared to the same period last year primarily due to increased coverage of fixed costs as a result of higher sales and to a lesser extent a more favorable customer and product mix.

Our Component Products Segment's cost of sales as a percentage of net sales improved 2% for the first nine months of 2025 compared to the same period in 2024. As a result, gross margin as a percentage of net sales increased over the same period. The increase in the gross margin percentage for the nine-month comparative period is primarily due to a higher gross margin percentage at the marine components reporting unit, partially offset by a lower gross margin percentage at the security products reporting unit. Marine components' gross margin as a percentage of net sales increased for the first nine months of 2025 compared to the same period last year primarily due to increased coverage of fixed costs as a result of higher sales and to a lesser extent a more favorable customer and product mix. Security products' gross margin as a percentage of net sales for the first nine months of 2025 decreased compared to the same period in 2024 primarily due to higher employee-related costs including salaries, benefits and medical expense partially offset by increased coverage of fixed costs as result of higher sales.

 *Operating Income* – As a percentage of net sales, our Component Products Segment's operating income for the third quarter and the first nine months of 2025 increased compared to the same periods of 2024 and was primarily impacted by the factors affecting sales, cost of sales and gross margin discussed above.

*Outlook –* Our Component Products Segment's sales for the first nine months of 2025 reflect sustained demand across both of its segments, with year-to-date results exceeding those for the same period in 2024. Marine components sales and operating income for the first nine months of 2025 exceeded prior year levels, driven by improved demand in the government and industrial markets as well as increased sales to the towboat market primarily in the first quarter of 2025 related to a one-time stocking event for a towboat OEM customer. Security products sales improved from prior year primarily due to increased sales to the government security market. Raw material price increases that began in the third quarter of 2024 have persisted through the first nine months of 2025. Additionally, our Component Products Segment began incurring tariff-related surcharges on certain components, primarily electronic components from Asia, beginning late in the second quarter of 2025. Our Component Products Segment expects these cost pressures to continue through the remainder of the year.

Our Component Products Segment expects security products net sales in 2025 to improve over 2024 primarily due to continued higher sales to the government security market. However, our Component Products Segment expects softness in various other markets to partially offset these gains, primarily the transportation and tool storage markets. The security products reporting unit's gross margin and operating income percentages are expected to be slightly below prior year levels due to the impact of higher-cost inventory and tariff-related surcharges. Our Component Products Segment expects marine components net sales to increase in 2025 predominantly due to higher expected sales to the government and industrial markets as well as the one-time stocking event for a towboat OEM customer in the first quarter of 2025. Overall, our Component Products Segment expects the marine components reporting unit to have improved gross margin and operating income percentages in 2025 compared to 2024 due to increased coverage of fixed costs on higher expected sales volumes.

Our Component Products Segment manufactures substantially all of its products in the U.S. and sources a substantial majority of its raw materials from U.S. suppliers. It also sources certain components, primarily electronic components from Asia, including China. Early in the first quarter of 2025, in anticipation of the U.S. federal government tariffs announcements, our Component Products Segment increased purchases of certain electronic components and other components to mitigate the potential near-term impact of tariffs. As noted above, late in the second quarter our Component Products Segment began incurring tariff-related surcharges on certain raw materials, primarily electronic components. In addition to tariffs on imported raw materials and components, some of its U.S. based suppliers have recently begun to implement tariff-related surcharges on certain U.S. based purchases. Where possible, our Component Products Segment is increasing selling prices to its customers to recoup these increased raw material costs, although the extent to which it can fully recover such costs will depend on a variety of factors including the ultimate tariff rate, the length of time tariffs are in effect, and the ability of its customers to substitute alternative products. Our Component Products Segment will continue to monitor current and anticipated near-term customer demand levels to ensure its production capabilities and inventories are aligned accordingly.

Our Component Products Segment's expectations for its operations and the markets it serves are based on a number of factors outside its control. Currently, our Component Products Segment's supply chains are stable and transportation and logistical delays are

<sup>**Table of Contents**</sup>

minimal. Our Component Products Segment has experienced global and domestic supply chain challenges in the past, and any future impacts on its operations will depend on, among other things, any future disruption in its operations or its suppliers' operations, the effect of tariffs and the impact of economic conditions, consumer confidence and geopolitical events on demand for our Component Products Segment's products or its customers' and suppliers' operations, all of which remain uncertain and cannot be predicted.

**Real Estate Management and Development** –

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three months ended** | **Three months ended** | **Nine months ended** | **Nine months ended** |
|  | **September 30,** | **September 30,** | **September 30,** | **September 30,** |
|  | **2024** | **2025** | **2024** | **2025** |
|  | **(In millions)** | **(In millions)** | **(In millions)** | **(In millions)** |
| Net sales: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Land sales | $15.3 | $**6.6** | $52.2 | $**20.8** |
| &nbsp;&nbsp;&nbsp;&nbsp;Utility and other |  | **—** | .2 | **—** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total net sales | 15.3 | **6.6** | 52.4 | **20.8** |
| Cost of sales | 8.8 | **3.5** | 29.8 | **10.9** |
| Gross margin | $6.5 | $**3.1** | $22.6 | $**9.9** |
| Operating income  | $21.8 | $**19.7** | $36.0 | $**41.6** |

---

*General –* Our Real Estate Management and Development Segment consists of BMI and LandWell. BMI and LandWell own real property in Henderson, Nevada. LandWell is actively engaged in developing certain real estate in Henderson, Nevada including approximately 2,100 acres zoned for residential/planned community purposes.

LandWell began marketing land for sale in the residential/planned community in December 2013 and at September 30, 2025 approximately 20 saleable acres remain. In addition, outside of the community LandWell has been actively marketing and selling land zoned for commercial and light industrial use and at September 30, 2025 approximately 15 saleable acres remain. Contracts for land sales are negotiated on an individual basis, and sales terms and prices will vary based on such factors as location (including location within a planned community), expected development work and individual buyer needs. Although land may be under contract or land sales may be completed, we do not recognize revenue until we have satisfied the criteria for revenue recognition. In most instances buyers can cancel an escrow agreement with no financial penalties until shortly before the closing date. In some instances, LandWell will receive cash proceeds at the time the contract closes and record deferred revenue for some or all of the cash amount received, with such deferred revenue being recognized in subsequent periods. Substantially all of the land in the residential/planned community has been sold; however, we expect the development work to take two to three years to complete.

*Net Sales and Operating Income –* Substantially all of the net sales from our Real Estate Management and Development Segment in the third quarter and the first nine months of 2025 and 2024 were from land sales. We recognized $6.6 million in revenues on land sales during the third quarter of 2025 compared to $15.3 million in the third quarter of 2024 and $20.8 million in the first nine months of 2025 compared to $52.2 million in the same prior year period. All of the land sales revenues recognized in 2025 and 2024 are related to land sold in prior years. As noted above, we recognize revenue in our residential/planned community over time using cost-based input methods, and all of the land sales revenue we recognized in 2025 and 2024 was under this method of revenue recognition. Land sales revenue in the third quarter and the first nine months of 2025 decreased compared to the same prior year periods due to the decreased pace of development activity for previously sold parcels within the residential/planned community. The pace of development activities is dictated by a number of factors such as city permit and design approval, approval from the Nevada Department of Environmental Protection, labor and materials availability, and the amount of remaining development obligations. Cost of sales related to land sales revenues was $3.5 million and $10.9 million in the third quarter and the first nine months of 2025, respectively, compared to $8.8 million and $29.6 million in the third quarter and the first nine months of 2024, respectively. In addition we recognized income of $14.2 million and $34.2 million related to tax increment infrastructure reimbursement in the first nine months of 2024 and 2025, respectively.

*Outlook –* LandWell is focused on developing the land it manages for the residential/planned community in Henderson with sales primarily to residential builders. At September 30, 2025, substantially all of the land in the residential/planned community had been sold with approximately 20 saleable acres remaining. The sale of the remaining 20 acres closed in October 2025. At September 30, 2025 we have deferred revenue of $28.6 million related to post-closing obligations on land sales closed prior to 2024. Because we recognize revenue over time using cost-based inputs, we will continue to recognize revenue on land previously sold over the development period, although we have already received substantially all the cash proceeds related to these sales. We currently expect to take one to two years to complete our post-closing obligations. Any delays or curtailments in infrastructure development related to post-closing obligation activities will delay the amount of revenue we recognize on previously closed land sales. There are also 15 saleable acres zoned for light industrial and commercial use adjacent to the 2,100 acre residential/planned community. Approximately one-half

<sup>**Table of Contents**</sup>

of these acres is currently in escrow and is currently scheduled to close in the fourth quarter of 2025. Because this land is not in the residential/planned community we will recognize all the proceeds as land revenue when the sale closes. Under LandWell's development agreement with the City of Henderson, the issuance of a specified number of housing permits requires LandWell to complete certain large infrastructure projects. LandWell began construction on several of these community-wide large projects in late 2021 with the construction expected to continue for the next two to three years. We expect these land development costs in 2025 to be comparable to 2024 due to the timing of planned infrastructure projects and the availability of certain construction materials. Because these large projects relate to the entirety of the residential/planned community, the costs associated with these large projects are not part of the cost-based inputs used to recognize revenue, and therefore, this spending will not correlate to revenue recognition. However, this spending is expected to be eligible for tax increment reimbursement under our Owner Participation Agreement ("OPA") with the City of Henderson, and delays or curtailments in eligible infrastructure development activities will also delay LandWell's ability to submit completed costs to the City for approval of additional OPA note receivables. The maximum reimbursement under the OPA is $209 million. We have collected $46.2 million to date and expect to reach the maximum over the next 7 to 10 years.

#### General Corporate and Other Items – 2025 Compared to 2024
*Changes in the Market Value of Valhi Common Stock held by Subsidiaries* – Our subsidiaries, Kronos and NL, hold shares of our common stock. As discussed in the 2024 Annual Report, we account for our proportional interest in these shares of our common stock as treasury stock at Kronos' and NL's historical cost basis. The remaining portion of these shares of our common stock, which are attributable to the noncontrolling interest of Kronos and NL, are reflected in our Condensed Consolidated Balance Sheet at fair value. Kronos and NL recognize unrealized gains or losses on these shares of our common stock in the determination of each of their respective net income or loss. Under the principles of consolidation we eliminate any gains or losses associated with our common stock to the extent of our proportional ownership interest in each subsidiary. We recognized a loss of $.1 million in the third quarter of 2025 compared to a gain of $3.7 million in the third quarter of 2024 and a loss of $1.8 million in the first nine months of 2025 compared to a gain of $4.3 million in the first nine months of 2024 in our Condensed Consolidated Statements of Operations, which represents the unrealized gain (loss) in respect of these shares during such periods attributable to the noncontrolling interest of Kronos and NL.

*Gain on Remeasurement of Investment in TiO*<sub>2</sub> *Manufacturing Joint Venture* – We recognized a gain on the remeasurement of Kronos' investment in LPC of $64.5 million in the third quarter of 2024 as a result of the acquisition. See Note 18 to our Condensed Consolidated Financial Statements.

*Gain on Remeasurement of Earn-out Liability* – We recognized a gain on the remeasurement of Kronos' earn-out liability of $4.6 million in the third quarter of 2025. See Note 18 to our Condensed Consolidated Financial Statements.

*Interest Income and Other* – Interest income and other decreased $.8 million in the third quarter and $4.0 million in the first nine months of 2025 compared to the same periods of 2024 primarily due to lower average interest rates and decreased cash balances. See Note 12 to our Condensed Consolidated Financial Statements.

*Other General Corporate Items* – Corporate expenses were 11% higher in the third quarter of 2025 compared to the same period in 2024 primarily due to higher litigation fees and related costs. Corporate expenses in the first nine months of 2025 were comparable to the same period in 2024.

● litigation fees and related costs at NL of $1.1 million in the third quarter of 2025 compared to $.6 million in the third quarter of 2024 and $2.2 million in the first nine months of 2025 compared to $2.6 million in the first nine months of 2024; and

● environmental remediation and related costs of $.2 million in the third quarter of 2025 compared to $.5 million in the third quarter of 2024 and $2.4 million in the first nine months of 2025 compared to $2.2 million in the first nine months of 2024.

Overall, we currently expect that our net general corporate expenses in 2025 will be higher than in 2024 primarily due to income recognized in 2024 related to the settlement of a liability for an environmental remediation site in the fourth quarter of 2024. See Note 16 to our Condensed Consolidated Financial Statements.

The level of our litigation fees and related expenses varies from period to period depending upon, among other things, the number of cases in which we are currently involved, the nature of such cases and the current stage of such cases (e.g. discovery, pre-trial motions, trial or appeal, if applicable). See Note 16 to our Condensed Consolidated Financial Statements. If our current expectations regarding the number of cases in which we expect to be involved during 2025, or the nature of such cases were to change, our corporate expenses could be higher than we currently estimate.

<sup>**Table of Contents**</sup>

Obligations for environmental remediation and related costs are difficult to assess and estimate and it is possible that actual costs for environmental remediation and related costs will exceed accrued amounts or that costs will be incurred in the future for sites in which we cannot currently estimate the liability. If these events occur in 2025, our corporate expense could be higher than we currently estimate. In addition, we adjust our accruals for environmental remediation and related costs as further information becomes available to us or as circumstances change. Such further information or changed circumstances could result in an increase or reduction in our accrued environmental remediation and related costs. See Note 16 to our Condensed Consolidated Financial Statements.

*Interest Expense* – Interest expense increased $1.5 million in the third quarter of 2025 and $5.3 million in the first nine months of 2025 compared to the same periods in 2024 primarily due to higher overall debt levels and higher average interest rates as a result of Kronos debt transactions entered into in 2024. Interest expense in the first nine months of 2024 includes a charge of $1.5 million for the write-off of deferred financing costs. See Note 7 to our Condensed Consolidated Financial Statements.

We expect interest expense will be higher in 2025 as compared to 2024 primarily due to the higher debt balances as a result of the third quarter acquisition of LPC and higher interest rates on Kronos' new debt issued in 2024 and 2025.

*Income Tax Expense* – We recognized income tax expense of $14.3 million in the third quarter of 2025 compared to $34.3 million in the third quarter of 2024 and income tax expense of $30.3 million in the first nine months of 2025 compared to $46.6 million in the first nine months of 2024. The decrease in the third quarter and first nine months of 2025 is primarily due to lower earnings in 2025 and the jurisdictional mix of such earnings, partially offset by the increase to the valuation allowance against our business interest expense carryforwards and the impact of the German tax rate change on our German net deferred tax asset. During interim periods, our effective tax rate may not necessarily correspond to the current period income (loss) before taxes due to the application of accounting for income taxes in interim periods which requires us to base our effective rate on full year projections of pre-tax income (loss).

We recognize deferred income taxes with respect to the excess of the financial reporting carrying amount over the income tax basis of our direct investment in Kronos common stock because the exemption under GAAP to avoid such recognition of deferred income taxes is not available to us. At December 31, 2024, we recognized a deferred income tax liability with respect to our direct investment in Kronos of $49.6 million. There is a maximum amount (or cap) of such deferred income taxes we are required to recognize with respect to our direct investment in Kronos. The maximum amount of the cap is $153.6 million. During the first nine months of 2025, we recognized a non-cash deferred income tax benefit with respect to our direct investment in Kronos of $4.9 million for the decrease in the deferred income taxes required to be recognized with respect to the excess of the financial reporting carrying amount over the income tax basis of our direct investment in Kronos common stock, this decrease related to our equity in Kronos' net income during the period. We recognized a similar deferred income tax expense of $5.4 million in the first nine months of 2024. A portion of the net change with respect to the excess of the financial reporting carrying amount over the income tax basis of our direct investment in Kronos common stock during such periods related to our equity in Kronos' other comprehensive income (loss) items, and the amounts allocated to other comprehensive income (loss) items includes amounts related to our equity in Kronos' other comprehensive income (loss) items.

At December 31, 2024, we had significant German corporate and trade net operating loss ("NOL") carryforwards of $449.3 million (deferred tax asset "DTA" of $71.1 million) and $41.8 million (DTA of $4.5 million), respectively. Prior to December 31, 2024, and using all available evidence, we had concluded that no deferred income tax asset valuation allowance was required to be recognized with respect to such carryforwards, principally because (i) such carryforwards have an indefinite carryforward period, (ii) we have utilized a portion of such carryforwards during the most recent three-year period and (iii) we currently expect to utilize the remainder of such carryforwards over the long term. At September 30, 2025, we continue to conclude no valuation allowance is required to be recognized for our German DTAs although prior to the complete utilization of such carryforwards, if we were to generate additional losses in our German operations for an extended period of time, or if applicable laws were to change such that the carryforward periods were more limited, it is possible that we might conclude the benefit of such carryforwards would no longer meet the more-likely-than-not recognition criteria, at which point we would be required to recognize a valuation allowance against some or all of the then-remaining tax benefit associated with the carryforwards.

See Note 13 to our Condensed Consolidated Financial Statements for a tabular reconciliation of our statutory income tax provision to our actual tax provision.

*Noncontrolling Interest in Net Income of Subsidiaries* – Noncontrolling interest in operations of subsidiaries decreased in the first nine months of 2025 compared to the same period in 2024 primarily due to decreased operating income at Kronos. See Note 14 to our Condensed Consolidated Financial Statements.

<sup>**Table of Contents**</sup>

#### LIQUIDITY AND CAPITAL RESOURCES

#### Consolidated Cash Flows
***Operating Activities* –**

Trends in cash flows from operating activities (excluding the impact of significant asset dispositions and relative changes in assets and liabilities) are generally similar to trends in our operating income. In addition to the impact of the operating, investing and financing cash flows discussed below, changes in the amount of cash, cash equivalents and restricted cash we report from period to period can be impacted by changes in currency exchange rates, since a portion of our cash, cash equivalents and restricted cash is held by our non-U.S. subsidiaries.

Cash used in operating activities was $136.1 million in the first nine months of 2025 compared to cash used in operating activities of $1.8 million in the first nine months of 2024. This $134.3 million increase in cash used in operating activities in the first nine months of 2025 includes:

● consolidated operating income of $94.2 million in the first nine months of 2025, a decrease of $59.8 million compared to operating income of $154.0 million in the first nine months of 2024;

● higher cash paid for environmental remediation and related costs in 2025 of $56.7 million primarily due to the payment of a settlement for an environmental remediation site (see Note 16 to our Condensed Consolidated Financial Statements);

● lower amount of net cash used in 2025 of $14.4 million associated with relative changes in our receivables, inventories, land held for investment, payables and accrued liabilities;

● higher cash paid for interest in 2025 of $10.6 million primarily due to increased debt levels and higher average interest rates relative to the comparable period in 2024 and the timing of interest payments;

● higher net cash paid for income taxes in 2025 of $7.6 million primarily due to relative timing of payments;

● cash premium of $4.4 million on the issuance of Kronos' senior notes; and

● lower net contributions to our TiO <sub>2 </sub> manufacturing joint venture in 2025 of $2.7 million as the result of obtaining control of LPC in July 2024.

As noted in our discussion of our Real Estate Management and Development segment above, we have sold the majority of the land in our residential/planned community, and in accordance with our development agreement with the City of Henderson and our contractual obligations with builders, we expect to complete our land development obligations over the next two to three years. Because we have largely received cash proceeds from land sales, we expect LandWell to generate negative operating cash flows as it completes its required land development work.

Changes in working capital were affected by accounts receivable and inventory changes as shown below:

● Kronos' average days sales outstanding ("DSO") increased from December 31, 2024 to September 30, 2025 primarily due to the relative changes in the timing of collections.

● Kronos' average days sales in inventory, or DSI, decreased from December 31, 2024 to September 30, 2025 primarily due to higher cost of sales, including higher unabsorbed fixed costs, despite an increase in finished goods volumes.

● CompX's average DSO increased from December 31, 2024 to September 30, 2025 primarily as a result of a seasonal increase in sales during the third quarter as compared to the fourth quarter and the timing of sales and collections relative to the end of the quarter.

● CompX's average DSI increased from December 31, 2024 to September 30, 2025 primarily due to increased inventory at the security products reporting unit as a result of higher raw material and production costs and to meet expected customer demand, partially offset by lower days in inventory at the marine components reporting unit primarily due to higher sales volumes for the third quarter of 2025 as compared to the fourth quarter of 2024.

<sup>**Table of Contents**</sup>

For comparative purposes, we have also provided comparable prior period numbers below.

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **December 31,** <br>**2023** | **September 30,** <br>**2024** | **December 31,** <br>**2024** | **September 30,** <br>**2025** |
| Kronos: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Days sales outstanding | 66 days | 68 days | 62 days | 65 days |
| &nbsp;&nbsp;&nbsp;&nbsp;Days sales in inventory | 65 days | 60 days | 82 days | 79 days |
| CompX: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Days sales outstanding | 36 days | 39 days | 33 days | 41 days |
| &nbsp;&nbsp;&nbsp;&nbsp;Days sales in inventory | 95 days | 105 days | 94 days | 97 days |

---

We do not have complete access to the cash flows of our majority-owned subsidiaries, due in part to limitations contained in certain credit agreements of our subsidiaries and because we do not own 100% of these subsidiaries. A detail of our consolidated cash flows from operating activities is presented in the table below. Intercompany dividends have been eliminated.

---

| | | |
|:---|:---|:---|
|  | **Nine months ended**  | **Nine months ended**  |
|  | **September 30,**  | **September 30,**  |
|  | **2024** | **2025** |
|  | **(In millions)** | **(In millions)** |
| *Cash provided by (used in) operating activities:* |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Kronos | $23.2 | $**(89.6)** |
| &nbsp;&nbsp;&nbsp;&nbsp;Valhi exclusive of subsidiaries | 58.1 | **28.0** |
| &nbsp;&nbsp;&nbsp;&nbsp;CompX | 15.6 | **10.8** |
| &nbsp;&nbsp;&nbsp;&nbsp;NL exclusive of subsidiaries | 31.9 | **(23.0)** |
| &nbsp;&nbsp;&nbsp;&nbsp;Tremont exclusive of subsidiaries | .9 | **4.9** |
| &nbsp;&nbsp;&nbsp;&nbsp;BMI | 3.9 | **4.8** |
| &nbsp;&nbsp;&nbsp;&nbsp;LandWell | (11.8) | **3.4** |
| &nbsp;&nbsp;&nbsp;&nbsp;Eliminations and other | (123.6) | **(75.4)** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total | $(1.8) | $**(136.1)** |

---

#### Investing Activities –
During the nine months ended September 30, 2025, we spent $35.8 million in capital expenditures including $32.7 million in our Chemicals Segment and $3.1 million in our Component Products Segment.

#### Financing Activities –
During the nine months ended September 30, 2025:

● Kronos had net borrowings of $58.7 million on its revolving credit facility;

● Kronos International, Inc. ("KII") issued an additional €75 million principal amount of 9.50% Senior Secured Notes due 2029 (the "Additional Notes"), the proceeds of which were used to refinance the 3.75% Senior Secured Notes that matured in September 2025;

● we repaid $19.6 million under the Contran credit facility; and

● we paid aggregate quarterly dividends to Valhi stockholders of $.24 per share ($6.8 million).

The declaration and payment of future dividends, and the amount thereof, is discretionary and is dependent upon a number of factors including our current and future expected results of operations, financial condition, cash requirements for our businesses, contractual and other requirements and restrictions and other factors deemed relevant by our board of directors. The amount and timing of past dividends is not necessarily indicative of the amount or timing of any future dividends which might be paid. There are currently no contractual restrictions on the amount of dividends which we may pay. Distributions to noncontrolling interest in subsidiaries in the first nine months of 2025 are comprised of CompX dividends paid to shareholders other than NL, Kronos dividends paid to shareholders other than us and NL, and LandWell dividends paid to partners other than us and BMI.

<sup>**Table of Contents**</sup>

#### Outstanding Debt Obligations
At September 30, 2025, our consolidated indebtedness was comprised of:

● Valhi's $25.0 million outstanding on its $150 million credit facility with Contran which is due no earlier than December 31, 2026;

● €426.174 million aggregate outstanding on Kronos' 9.50% Senior Secured Notes due March 2029 ($502.3 million carrying amount, net of unamortized premium and unamortized debt issuance costs);

● $53.7 million outstanding on Kronos' subordinated, unsecured term loan from Contran due September 2029 (the "Contran Term Loan");

● $70.2 million outstanding on Kronos' revolving credit facility (the "Global Revolver"); and

● $11.1 million on LandWell's bank loan due April 2036.

Effective July 17, 2025, Kronos completed an amendment to its Global Revolver (the "Fourth Amendment"). Among other things, the Fourth Amendment increased the maximum borrowing amount from $300 million to $350 million and increased the Belgian and German sub-limits from €30 million and €60 million to €55 million and €85 million, respectively, allowing greater access to Euro denominated borrowings. The maturity date of the Global Revolver remains July 2029. On September 15, 2025, KII issued Additional Notes, the proceeds of which were used to refinance the 3.75% Senior Secured Notes (€75 million aggregate principal amount) that matured in September 2025. The Additional Notes were issued as additional notes to the existing €351.174 million aggregate principal amount of 9.50% Senior Secured Notes due 2029 issued on February 12, 2024 and July 30, 2024 (the "Existing Notes"). The Additional Notes were issued at a premium of 105.0% of their principal amount, resulting in net proceeds of approximately $90 million after fees and estimated expenses. The Additional Notes are fungible with the Existing Notes, are treated as a single series and have the same terms as the Existing Notes, other than their date of issuance and issue price. See Note 7 to our Condensed Consolidated Financial Statements.

The Contran Term loan is subordinated in right of payment to Kronos' Senior Secured Notes and its Global Revolver. Kronos' Senior Secured Notes, the Contran Term Loan and Kronos' Global Revolver contain a number of covenants and restrictions which, among other things, restrict its ability to incur or guarantee additional debt, incur liens, pay dividends or make other restricted payments, or merge or consolidate with, or sell or transfer substantially all of its assets to, another entity, and contain other provisions and restrictive covenants customary in lending transactions of these types. Our credit agreements contain provisions which could result in the acceleration of indebtedness prior to their stated maturity for reasons other than defaults for failure to comply with typical financial or payment covenants. For example, the credit agreements allow the lender to accelerate the maturity of the indebtedness upon a change of control (as defined in the agreement) of the borrower. In addition, the credit agreements could result in the acceleration of all or a portion of the indebtedness following a sale of assets outside the ordinary course of business. The terms of all of our debt instruments are discussed in Note 9 to our Consolidated Financial Statements included in our 2024 Annual Report. We are in compliance with all of our debt covenants at September 30, 2025. We believe we will be able to continue to comply with the financial covenants contained in our debt obligations through their maturity; however, if future operating results differ materially from our expectations we may be unable to maintain compliance.

Our assets consist primarily of investments in operating subsidiaries, and our ability to service our obligations, including Kronos' Senior Secured Notes and the Contran Term Loan, depends in part upon the distribution of earnings of our subsidiaries, whether in the form of dividends, advances or payments on account of intercompany obligations or otherwise. Kronos' Senior Secured Notes are collateralized by, among other things, a first priority lien on (i) 100% of the common stock or other ownership interests of each existing and future direct domestic subsidiary of KII and the guarantors, and (ii) 65% of the voting common stock or other ownership interests and 100% of the non-voting common stock or other ownership interests of each non-U.S. subsidiary that is directly owned by KII or any guarantor. Kronos' Global Revolver is collateralized by, among other things, a first priority lien on the borrower's trade receivables and inventories. See Note 7 to our Condensed Consolidated Financial Statements.

#### Future Cash Requirements
*Liquidity* –

Our primary source of liquidity on an ongoing basis is our cash flows from operating activities and borrowings under various lines of credit and notes. We generally use these amounts to (i) fund capital expenditures, (ii) repay short-term indebtedness incurred primarily for working capital purposes and (iii) provide for the payment of dividends (including dividends paid to us by our subsidiaries)

<sup>**Table of Contents**</sup>

or treasury stock purchases. From time-to-time we will incur indebtedness, generally to (i) fund short-term working capital needs, (ii) refinance existing indebtedness, (iii) make investments in marketable and other securities (including the acquisition of securities issued by our subsidiaries and affiliates) or (iv) fund major capital expenditures or the acquisition of other assets outside the ordinary course of business. Occasionally we sell assets outside the ordinary course of business, and we generally use the proceeds to (i) repay existing indebtedness (including indebtedness which may have been collateralized by the assets sold), (ii) make investments in marketable and other securities, (iii) fund major capital expenditures or the acquisition of other assets outside the ordinary course of business or (iv) pay dividends.

We routinely compare our liquidity requirements and alternative uses of capital against the estimated future cash flows we expect to receive from our subsidiaries, and the estimated sales value of those units. As a result of this process, we have in the past sought, and may in the future seek, to raise additional capital, refinance or restructure indebtedness, repurchase indebtedness in the market or otherwise, modify our dividend policies, consider the sale of our interests in our subsidiaries, affiliates, business units, marketable securities or other assets, or take a combination of these and other steps, to increase liquidity, reduce indebtedness and fund future activities. Such activities have in the past and may in the future involve related companies. We may also from time to time engage in preliminary discussions with existing or potential investors regarding the timing or terms of any such refinancing or other potential transaction. From time to time, we and our subsidiaries may enter into intercompany loans as a cash management tool. Such notes are structured as revolving demand notes and pay and receive interest on terms we believe are generally more favorable than current debt and investment market rates. The companies that borrow under these notes have sufficient liquidity to repay the notes. All of these notes and related interest expense and income are eliminated in our Condensed Consolidated Financial Statements.

We periodically evaluate acquisitions of interests in or combinations with companies (including our affiliates) that may or may not be engaged in businesses related to our current businesses. We intend to consider such acquisition activities in the future and, in connection with this activity, may consider issuing additional equity securities and increasing indebtedness. From time to time, we also evaluate the restructuring of ownership interests among our respective subsidiaries and related companies.

Based upon our expectations of our operating performance, and the anticipated demands on our cash resources, we expect to have sufficient liquidity to meet our short-term (defined as the twelve-month period ending September 30, 2026) and long-term obligations (defined as the five-year period ending September 30, 2030). Kronos' Global Revolver matures in July 2029, and at September 30, 2025 Kronos had total availability for borrowing of approximately $342 million less any amounts outstanding. The borrowing base is calculated at least quarterly, and the amount available for borrowing may change based on applicable period end balances. See Note 7 to our Condensed Consolidated Financial Statements. If actual developments differ from our expectations, our liquidity could be adversely affected.

At September 30, 2025, we had an aggregate of $232.8 million of restricted and unrestricted cash, cash equivalents and marketable securities, including $34.6 million held by our non-U.S. subsidiaries. A detail by entity is presented in the table below.

---

| | | |
|:---|:---|:---|
|  | **Total** <br>**amount** | **Held outside** <br>**U.S.** |
|  | **(In millions)** | **(In millions)** |
| Kronos | $**36.4** | $**34.6** |
| CompX | **46.3** | **—** |
| NL exclusive of its subsidiaries | **77.3** | **—** |
| BMI | **14.6** | **—** |
| Tremont exclusive of its subsidiaries | **12.2** | **—** |
| LandWell | **46.0** | **—** |
| Valhi exclusive of its subsidiaries | **—** | **—** |
| Total cash and cash equivalents, restricted cash and marketable securities | $**232.8** | $**34.6** |

---

*Capital Expenditures and Other –*

We currently expect our aggregate capital expenditures for 2025 will be approximately $49 million as follows:

● $45 million by our Chemicals Segment; and

● $4 million by our Component Products Segment.

In addition, LandWell expects to spend approximately $30 million on land development costs during 2025.

<sup>**Table of Contents**</sup>

Capital spending for 2025 is expected to be funded through cash generated from operations or borrowing under our existing credit facilities. Planned capital expenditures for the remainder of 2025 at Kronos and CompX will primarily be to maintain and improve our existing facilities. It is possible we will delay planned capital projects based on market conditions including but not limited to expected demand and the general availability of materials, equipment and supplies necessary to complete such projects.

*Repurchases of Common Stock –*

We, Kronos and CompX have programs to repurchase common stock from time to time as market conditions permit. These stock repurchase programs do not include specific price targets or timetables and may be suspended at any time. Depending on market conditions, these programs may be terminated prior to completion. Cash on hand will be used to acquire the shares, and repurchased shares will be added to treasury shares and cancelled.

At September 30, 2025, Valhi had approximately .3 million shares available to repurchase under authorizations made by our board of directors.

Kronos' board of directors previously authorized the repurchase of up to 2.0 million shares of its common stock in open market transactions, including block purchases, or in privately-negotiated transactions at unspecified prices and over an unspecified period of time. Kronos may repurchase its common stock from time to time as market conditions permit. At September 30, 2025, approximately 1.0 million shares were available for repurchase under these authorizations.

CompX's board of directors previously authorized the repurchase of its Class A common stock in open market transactions, including block purchases, or in privately-negotiated transactions at unspecified prices and over an unspecified period of time. At September 30, 2025, approximately .5 million shares were available for repurchase under these authorizations.

*Dividends –*

Because our operations are conducted primarily through subsidiaries and affiliates, our long-term ability to meet parent company level corporate obligations is largely dependent on the receipt of dividends or other distributions from our subsidiaries and affiliates. In February 2025 the Kronos board of directors approved a quarterly dividend of $.05 per share. If Kronos were to pay its $.05 per share dividend in each quarter of 2025 based on the 58.0 million shares we held of Kronos common stock at September 30, 2025, during 2025 we would receive aggregate regular dividends from Kronos of $11.6 million. In February 2025 the NL board of directors approved a quarterly dividend of $.09 per share. If NL were to pay its $.09 per share dividend in each quarter of 2025 based on the 40.4 million shares we held of NL common stock at September 30, 2025, during 2025 we would receive aggregate quarterly dividends from NL of $14.5 million. In August 2025 the NL board of directors declared a special dividend of $.21 per share on its common stock. We received $8.5 million from this dividend, which is not expected to be recurring. BMI and LandWell pay cash dividends from time to time, but the timing and amount of such dividends are uncertain. In this regard, we received aggregate dividends from BMI and LandWell of $7.8 million in 2025. We do not know if we will receive additional dividends from BMI and LandWell during 2025. All of our ownership interest in CompX is held through our ownership in NL; as such we do not receive any dividends from CompX. Instead any dividend paid by CompX is paid to NL.

Our subsidiaries have various credit agreements with unrelated third-party lenders which contain customary limitations on the payment of dividends; however, these restrictions in the past have not significantly impacted their ability to pay dividends.

*Investment in our Subsidiaries and Affiliates and Other Acquisitions –*

We have in the past, and may in the future, purchase the securities of our subsidiaries and affiliates or third parties in market or privately-negotiated transactions. We base our purchase decisions on a variety of factors, including an analysis of the optimal use of our capital, taking into account the market value of the securities and the relative value of expected returns on alternative investments. In connection with these activities, we may consider issuing additional equity securities or increasing our indebtedness. We may also evaluate the restructuring of ownership interests of our businesses among our subsidiaries and related companies.

We generally do not guarantee any indebtedness or other obligations of our subsidiaries or affiliates. Our subsidiaries are not required to pay us dividends. If one or more of our subsidiaries were unable to maintain its current level of dividends, either due to restrictions contained in a credit agreement or to satisfy its liabilities or otherwise, our ability to service our liabilities or to pay dividends on our common stock could be adversely impacted. If this were to occur, we might consider reducing or eliminating our dividends or selling interests in subsidiaries or other assets. If we were required to liquidate assets to generate funds to satisfy our liabilities, we might be required to sell at less than what we believe is the long-term value of such assets.

<sup>**Table of Contents**</sup>

We have a $50 million revolving credit facility with a subsidiary of NL secured with approximately 35.2 million shares of the common stock of Kronos held by NL's subsidiary as collateral. Outstanding borrowings under the credit facility, as amended, bear interest at the prime rate plus 1.875% per annum, payable quarterly, with all amounts due on December 31, 2030. The maximum principal amount which may be outstanding from time-to-time under the credit facility is limited to 50% of the value of the Kronos stock using the most recent closing price. The credit facility contains a number of covenants and restrictions which, among other things, restrict NL's subsidiary's ability to incur additional debt, incur liens, and merge or consolidate with, or sell or transfer substantially all of NL's subsidiary's assets to, another entity, and require NL's subsidiary to maintain a minimum specified level of consolidated net worth. Upon an event of default (as defined in the credit facility), Valhi will be entitled to terminate its commitment to make further loans to NL's subsidiary, declare the outstanding loans (with interest) immediately due and payable, and exercise its rights with respect to the collateral under the loan documents. Such collateral rights include, upon certain insolvency events with respect to NL's subsidiary or NL, the right to purchase all of the Kronos common stock at a purchase price equal to the aggregate market value, less amounts owing to Valhi under the loan documents, and up to 50% of such purchase price may be paid by Valhi in the form of an unsecured promissory note bearing interest at the prime rate plus 2.75% per annum, payable quarterly, with all amounts due no later than five years from the date of purchase, with the remainder of such purchase price payable in cash at the date of purchase. We also eliminate any such intercompany borrowings in our Condensed Consolidated Financial Statements. There is $.5 million outstanding under this facility at September 30, 2025.

We also have an unsecured revolving demand promissory note with CompX which, as amended, provides for borrowings from CompX of up to $25 million. We eliminate these intercompany borrowings in our Condensed Consolidated Financial Statements. The facility, as amended, is due on demand, but in any event no earlier than December 31, 2026. We had gross borrowings of $10.7 million and gross repayments of $11.9 million during the first nine months of 2025, and $8.1 million was outstanding at September 30, 2025. We could borrow $16.9 million under our current intercompany facility with CompX at September 30, 2025. CompX's obligation to loan us money under this note is at CompX's discretion.

#### Commitments and Contingencies
There have been no material changes in our contractual obligations since we filed our 2024 Annual Report and we refer you to that report for a complete description of these commitments.

We are subject to certain commitments and contingencies, as more fully described in our 2024 Annual Report, or in Notes 13, 16 and 18 to our Condensed Consolidated Financial Statements and in Part II, Item 1 of this Quarterly Report, including:

● certain income tax contingencies in various U.S. and non-U.S. jurisdictions;

● certain environmental remediation matters involving NL and BMI;

● certain litigation related to NL's former involvement in the manufacture of lead pigment and lead-based paint; and

● certain other litigation to which we are a party.

In addition to such legal proceedings, various legislation and administrative regulations have, from time to time, been proposed that seek to (i) impose various obligations on present and former manufacturers of lead pigment and lead-based paint (including NL) with respect to asserted health concerns associated with the use of such products and (ii) effectively overturn court decisions in which NL and other pigment manufacturers have been successful. Examples of such proposed legislation include bills which would permit civil liability for damages on the basis of market share, rather than requiring plaintiffs to prove that the defendant's product caused the alleged damage, and bills which would revive actions barred by the statute of limitations. While no legislation or regulations have been enacted to date that are expected to have a material adverse effect on our consolidated financial position, results of operations or liquidity, enactment of such legislation could have such an effect.

#### Recent Accounting Pronouncements
See Note 19 to our Condensed Consolidated Financial Statements.

#### Critical Accounting Policies and Estimates
For a discussion of our critical accounting policies and estimates, refer to Part I, Item 7 - "Management's Discussion and Analysis of Financial Condition and Results of Operations" in our 2024 Annual Report. There have been no changes in our critical accounting policies or estimates during the first nine months of 2025 except as described below:

<sup>**Table of Contents**</sup>

*Goodwill* – Our net goodwill related to our Chemicals Segment totaled $355.2 million at September 30, 2025 primarily resulting from our various step acquisitions of Kronos and NL (which occurred before the implementation of the current accounting standards related to noncontrolling interest) and Kronos' purchase of the remaining 50% interest in LPC in 2024. In accordance with the applicable accounting standards for goodwill, we do not amortize goodwill.

We perform a goodwill impairment test annually in the third quarter of each year by reporting unit. Goodwill is also evaluated for impairment at other times whenever an event occurs or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying value. An entity may first assess qualitative factors to determine whether it is necessary to complete the quantitative impairment test using a more-likely-than-not criteria. If an entity believes it is more-likely-than-not the fair value of a reporting unit is greater than its carrying value, including goodwill, the quantitative impairment test can be bypassed. Alternatively, an entity has an unconditional option to bypass the qualitative assessment and proceed directly to performing the quantitative impairment test. If the Company chooses not to complete a qualitative assessment for a reporting unit or if the initial assessment indicates that it is more likely than not that the carrying value of a reporting unit exceeds its estimated fair value, additional quantitative testing is required.

If additional quantitative testing is performed, an impairment loss is recognized when the amount by which the carrying value of the reporting unit exceeds its fair value. A reporting unit can be a segment or an operating division based on the operations of the segment. Our Chemicals Segment is one reporting unit.

In performing a quantitative test for impairment of goodwill, we use the income approach method of valuation that includes the discounted cash flow method and the market approach that includes the guideline public company method to determine the fair value of the reporting unit. When performing an income approach method considerable management judgement is necessary to derive the primary assumptions used in estimating fair value under the discounted cash flow model including forecasted revenue, gross margin, operating expenses, capital expenditures, discount rate and the tax rate. Additionally, management judgement is necessary for the assumptions used to determine fair value under the guideline public company method including the selection of guideline companies and the valuation multiples applied. We performed our annual goodwill impairment test in the third quarter of 2025 for our Chemicals Segment goodwill and concluded there was no impairment of such goodwill.

Estimating the fair value of a reporting unit requires the use of estimates and significant judgments that are based on a number of factors including actual operating results and future expectations such as global demand, product pricing, input costs and general economic trends. The judgements and estimates described above could change in future periods or the actual results may differ from the forecast and could result in the recognition of a material goodwill impairment.

---

| | |
|:---|:---|
| **ITEM 3.** | **QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK** |

---

We are exposed to market risk, including currency exchange rates, interest rates, equity security prices, and raw material prices. There have been no material changes in these market risks since we filed our 2024 Annual Report, and refer you to Part I, Item 7A. *–* "Quantitative and Qualitative Disclosure About Market Risk" in our 2024 Annual Report.

---

| | |
|:---|:---|
| **ITEM 4.** | **CONTROLS AND PROCEDURES** |

---

*Evaluation of Disclosure Controls and Procedures*

We maintain disclosure controls and procedures which, as defined in Exchange Act Rule 13a-15(e), means controls and other procedures that are designed to ensure that information required to be disclosed in the reports we file or submit to the SEC under the Securities Exchange Act of 1934, as amended (the "Act"), is recorded, processed, summarized and reported, within the time periods specified in the SEC's rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information we are required to disclose in the reports we file or submit to the SEC under the Act is accumulated and communicated to our management, including our principal executive officer and our principal financial officer, or persons performing similar functions, as appropriate to allow timely decisions to be made regarding required disclosure. Each of Michael S. Simmons, our Vice Chairman of the Board, President and Chief Executive Officer, and Amy Allbach Samford, our Executive Vice President and Chief Financial Officer, have evaluated the design and effectiveness of our disclosure controls and procedures as of September 30, 2025. Based upon their evaluation, these executive officers have concluded that our disclosure controls and procedures were effective as of the date of such evaluation.

*Internal Control over Financial Reporting*

Our management is responsible for establishing and maintaining adequate internal control over financial reporting which, as defined by Exchange Act Rule 13a-15(f) means a process designed by, or under the supervision of, our principal executive and principal

<sup>**Table of Contents**</sup>

financial officers, or persons performing similar functions, and effected by the board of directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles, and includes those policies and procedures that:

● Pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of our assets,

● Provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with GAAP, and that receipts and expenditures are being made only in accordance with authorizations of management and directors, and

● Provide reasonable assurance regarding prevention or timely detection of an unauthorized acquisition, use or disposition of assets that could have a material effect on our Condensed Consolidated Financial Statements.

*Other*

As permitted by the SEC, our assessment of internal control over financial reporting excludes internal control over the preparation of any financial statement schedules which would be required by Article 12 of Regulation S-X.

*Changes in Internal Control over Financial Reporting*

There has been no change to our internal control over financial reporting during the quarter ended September 30, 2025 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

**Part II. OTHER INFORMATION**

#### ITEM 1. Legal Proceedings .
Refer to Note 16 to our Condensed Consolidated Financial Statements, our June 30, 2025 Quarterly Report on Form 10-Q and our 2024 Annual Report for descriptions of certain legal proceedings.

#### ITEM 1A. Risk Factors .
For a discussion of the risk factors related to our businesses, please refer to Part I, Item 1A, "Risk Factors," in our 2024 Annual Report.

<sup>**Table of Contents**</sup>

#### ITEM 6. Exhibits .

---

| | |
|:---|:---|
| **ITEM No.** | **Exhibit Index** |
| 10.1 | [Third Supplemental Indenture dated as of September 15, 2025, by and among Kronos International, Inc., the guarantors named therein, and Deutsche Bank Trust Company Americas, as trustee, collateral agent, paying agent, transfer agent and registrar – incorporated by reference to Exhibit 10.1 to Kronos Worldwide, Inc.'s Current Report on Form 8-K filed September 15, 2025.](https://www.sec.gov/Archives/edgar/data/1257640/000125764025000034/kro-20250915xex10d1.htm)<br>|
| 10.2 | [Additional Notes Priority Joinder Agreement dated September 15, 2025, executed by Deutsche Bank Trust Company Americas, as trustee and collateral agent – incorporated by reference to Exhibit 10.2 to Kronos Worldwide, Inc.'s Current Report on Form 8-K filed September 15, 2025.](https://www.sec.gov/Archives/edgar/data/1257640/000125764025000034/kro-20250915xex10d2.htm)<br>|
| 31.1 | [Certification](vhl-20250930xex31d1.htm) |
| 31.2 | [Certification](vhl-20250930xex31d2.htm) |
| 32.1 | [Certification](vhl-20250930xex32d1.htm) |
| 101.INS | Inline XBRL Instance – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. |
| 101.SCH | Inline XBRL Taxonomy Extension Schema |
| 101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase |
| 101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase |
| 101.LAB | Inline XBRL Taxonomy Extension Label Linkbase |
| 101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase |
| 104 | Cover page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) |

---

<sup>**Table of Contents**</sup>

#### SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  |  | **VALHI, INC.** |
|  |  | **(Registrant)** |
| Date: | November 6, 2025 | /s/ Amy Allbach Samford |
|  |  | Amy Allbach Samford<br>(Executive Vice President and Chief Financial Officer) |
| Date: | November 6, 2025 | /s/ Patty S. Brinda |
|  |  | Patty S. Brinda<br>(Vice President and Controller) |

---

## Exhibit 31.1

**Exhibit 31.1**

I, Michael S. Simmons, certify that:

1) I have reviewed this Quarterly Report on Form 10-Q of Valhi, Inc.;

2) Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3) Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4) The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting;

5) The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent function):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: November 6, 2025

---

| |
|:---|
| /s/ Michael S. Simmons |
| Michael S. Simmons |
| Vice Chairman of the Board, President and Chief Executive Officer |

---

------

## Exhibit 31.2

**Exhibit 31.2**

I, Amy A. Samford, certify that:

1) I have reviewed this Quarterly Report on Form 10-Q of Valhi, Inc.;

2) Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3) Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4) The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting;

5) The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent function):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: November 6, 2025

---

| |
|:---|
| /s/Amy A. Samford |
| Amy A. Samford |
| Executive Vice President and Chief Financial Officer  |

---

------

## Exhibit 32.1

**Exhibit 32.1**

**CERTIFICATION PURSUANT TO**

**18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO**

**SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the Quarterly Report of Valhi, Inc. (the "Company") on Form 10-Q for the quarter ended September 30, 2025 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), we, Michael S. Simmons, Vice Chairman of the Board, President and Chief Executive Officer, and Amy A. Samford, Executive Vice President and Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

---

| | |
|:---|:---|
| /s/ Michael S. Simmons | /s/ Amy A. Samford |
| Michael S. Simmons<br>Vice Chairman of the Board, President and <br>&nbsp;&nbsp;&nbsp;&nbsp;Chief Executive Officer <br>November 6, 2025 | Amy A. Samford<br>Executive Vice President and Chief Financial Officer <br>November 6, 2025 |

---

Note:&nbsp;&nbsp;&nbsp;&nbsp;The certification the registrant furnishes in this exhibit is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. Registration Statements or other documents filed with the Securities and Exchange Commission shall not incorporate this exhibit by reference, except as otherwise expressly stated in such filing.

------